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ABSTRACT
Gastrointestinal diseases such as inflammatory bowel diseases (IBD) and
colorectal cancer (CRC) are pathological conditions associated with chronic
inflammation, characterized by intestinal damage, debilitating symptoms, and
detrimental health consequences. The increased risk of CRC in IBD patients, and
the adverse effects associated with current therapeutic strategies, point out the
need for safer alternatives to reduce chronic inflammation in the bowel. Lunasin
is a bioactive peptide naturally occurring in soybeans, with chemopreventive and
anti-inflammatory properties demonstrated in several extra-intestinal diseases.
However, to date, there is no evidence of the biological activity of lunasin on the
gastrointestinal tract as a target site. The objective of this research was to
investigate the biological activity of lunasin against bowel-related diseases using
in vivo models. First, lunasin was isolated from tofu wastewater applying a
designed process that combines precipitation techniques and chromatographic
purification. The three-step isolation process was applied to industrially produced
tofu wastewater yielding 773mg lunasin of 80% purity per kg dry tofu whey, with
anti-inflammatory properties as tested in vitro using activated murine
macrophages. Then, the anti-inflammatory activity of lunasin in the gut was
determined using an in vivo model of spontaneous colitis. Oral administration of
lunasin reduced pro-inflammatory cytokines throughout the small and large
intestines and decreased the frequency of clinical manifestations of IBD in IL-10-/mice. In vitro analysis indicated that the mechanism of action is partially
vi

associated with the ability of lunasin to modulate the activation of the NLRP3
inflammasome. Finally, the chemopreventive activity of lunasin in the bowel was
evaluated using an in vivo model of colitis-associated CRC. Oral administration
of lunasin decreased the impact of inflammation over the colon, facilitated
recovery from episodes of mild and moderate inflammation, reduced tumor
burden, and mitigated the progression of malignant features. The results of this
study demonstrate: 1) the presence of bioactive lunasin in tofu wastewater, 2) the
anti-inflammatory and chemopreventive activity of lunasin in the bowel, and 3)
the modulatory activity of lunasin over the NLRP3 inflammasome. This research
can serve as a basis for further investigation on the active incorporation of
lunasin for the management of IBD.
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CHAPTER 1. INTRODUCTION
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1.1 Abstract
Inflammatory bowel disease (IBD) is a debilitating health condition that can
lead to detrimental and life-threatening consequences. Genetic susceptibility,
environmental conditions, a compromised intestinal epithelial barrier, and
dysregulation of the intestinal microbiota, are all risk factors that contribute to the
impairment of intestinal homeostasis. When this happens, the immune system is
triggered, and cytokines come into play to drive the initiation and control
progression and maintenance of a state of chronic inflammation in the bowel.
Diet has been suggested as one of the main factors contributing to IBD, with
bioactive compounds from plant-based foods potentially providing a protective
effect. The widely recognized bioactive properties of the soybean peptide
lunasin, make it a potential candidate for the management of inflammationrelated diseases. However, lunasin research has been focused on extraintestinal
conditions, and to date the knowledge about the interaction of lunasin with the
gastrointestinal tract is incipient. Therefore, studying the biological activity of
lunasin in the bowel, and particularly in the context of inflammation, is essential
to identify its potential utilization for the management of bowel-inflammation
related diseases.
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1.2 Literature Review
Exposure to potentially harmful elements is inherent to the interaction with
the environment around us. Inflammation, when properly regulated and resolved,
is one of the most efficient mechanisms of defense that our body has developed
to ensure our survival and maintain our integrity. However, when inflammation is
subnormal, excessive, or fails to resolve, it becomes harmful to the host and
results in negative consequences. Non-resolved inflammation is currently
considered a major driver of diseases and has directly been linked to diverse
chronic conditions such as asthma, atherosclerosis, neurodegenerative diseases,
rheumatoid arthritis, obesity, IBD, and cancer [1].
1.2.1 The gastrointestinal tract and inflammatory bowel disease
The gastrointestinal tract (GIT) is one of the most complex entities in the
human body. In the GIT, the symbiotic relationship between the intestinal
epithelium and a wide diversity of commensal microbiota orchestrate the
processes required for nutrition, mediating the breakdown of food components,
the selective absorption of nutrients, and the exclusion of waste and harmful
compounds from the body [2]. With about 5 meters in length and 32 m2 surface
area [3], the GIT provides one of the largest interfaces between our body and the
external environment. A thick layer of mucus, secretory immunoglobulins,
enzymes, and antimicrobial peptides, among other components, contribute to the
physical barrier created by the intestinal epithelium, and in conjunction with the
immune system, regulate the safe interaction with the microbiota and the
2

components in the luminal content [2]. While in healthy individuals antiinflammatory mechanisms prevent spontaneous inflammation and contribute to
the resolution of episodes of acute inflammation, facilitating intestinal
homeostasis, dietary and environmental factors leading to persistent
inflammatory stimuli, abnormal immune response, and inappropriate antiinflammatory regulation, contribute to the initiation and maintenance of nonresolved inflammation [1].
IBD is a debilitating condition of chronic inflammation of the
gastrointestinal mucosa [4], that not only affects the well-being and impairs the
quality of life of the patients, but can lead to life-threatening conditions such as
bowel perforation, toxic megacolon, and cancer [4,5]. More than 6.8 million
people are estimated to live with IBD worldwide [6], and newly industrialized
countries in Africa, Asia, and South America show an accelerating incidence as
their societies become more westernized [7]. In the USA, patients with IBD incur
over three-fold higher direct costs (around $23,000 per member per year) than
people not affected by IBD due to health care utilization, treatment with specific
therapeutics, out-of-pocket expenditures, and workplace productivity losses [8].
Crohn’s disease (CD) and ulcerative colitis (UC) are the two major forms
of IBD. Although CD is more common in areas between the terminal ileum and
the perianal area, it can affect the entire thickness of the bowel in any section of
the GIT, in a characteristic discontinuous pattern in which healthy regions of the
intestine are mixed with inflamed areas [9]. In contrast, UC only affects the
3

innermost lining of the intestinal wall (the mucosa), begins in the most distal
region of the bowel, the rectum, and progresses continuously toward the
ascending, transverse and descending colon, being limited to the large intestine
[9]. Symptoms of IBD depend on the localization of the affected area and the
level of involvement, but the most common clinical manifestations include
diarrhea, rectal bleeding, loss of body weight, abdominal pain, appetite changes,
nausea, vomiting, and in the most severe cases physiological manifestations
associated with bowel obstruction, infection, malnutrition, anemia, among others
can occur [4]. But the effects of inflammation in IBD are not only limited to the
gut. Extraintestinal manifestations are commonly observed in 25 to 40% of IBD
patients and involve the skin, eyes, skeletal muscle, liver, kidneys, and the
metabolic system [10].
Cardiovascular disease and colorectal cancer (CRC) account for the most
common causes of death among IBD patients [5]. Indeed, increased circulating
levels of pro-inflammatory mediators such as TNF-α and nitric oxide, bacterial
endotoxins reaching systemic circulation due to disruption of the intestinal
barrier, resulting from the inflammatory burden in the bowel, have been
associated with arterial stiffening, venous thromboembolism, and atherosclerosis,
events that contribute to an increased risk of cardiovascular failure [11]. The
correlation between IBD and cancer has been largely studied. As reviewed by
Chang and coworkers, IBD patients are at increased risk of developing intestinal
and extra-intestinal malignancies. When compared to the regular population:
4

patients with extensive UC have a 19 times higher risk of CRC, and CD patients
20- to 30-fold increased risk of small bowel cancer, while hematological and skin
cancers, and to a lower extent cervical and urinary cancers are potential
consequences of the immunosuppressive effects of therapeutics for the
treatment of IBD [12]. Although the specific risk of colitis-associated CRC, the
most prevalent type of cancer in IBD, depends on the characteristics of the
studied population, it is commonly recognized that young age at the onset of
colitis, anatomical location, long duration of the disease, and family history of
CRC are the major risk factors [13].
Management of IBD is personalized based on disease severity, anatomic
location, underlying complications, potential adverse effects, and previous
response to medication [4,14]. Current pharmacological alternatives include short
interventions with corticosteroids to induce remission in periods of active flares,
and individual or combined therapy with aminosalicylates, immunomodulators,
antimetabolites, and biologics to maintain remission, which are regularly
accompanied by parenteral nutrition and nutrition supplementation to overcome
malnutrition complications [15]. These therapeutics act as immunosuppressants,
resulting in an inherently increased risk of opportunistic infections, and have
been associated with adverse effects such as peptic ulcers, renal dysfunction,
hepatotoxicity, pancreatitis, pulmonary fibrosis, hypertension, and increased risk
of other malignancies [16,17].

5

1.2.2 Risk factors contributing to the pathogenesis of IBD.
Although no agreement has been reached about the specific cause of
IBD, important signs of progress have been made revealing the interplay
between internal and external factors that include genetic susceptibility of the
host, environmental triggers, intestinal microbiota, the immune system, and the
intestinal epithelial barrier [18].
1.2.2.1 Genetic susceptibility
As reviewed by De Lange and Barret, 163 susceptibility loci associated
with the epithelial barrier (CDH1, ERRF11), innate mucosal defense (CARD9,
NOD2), autophagy (CUL2, DAP), apoptosis (MST1, PUS10), activation and
regulation of adaptive immune response (JAK2, STAT3, NFKB1, REL), as well
as those involved in cytokines production (TNF-α, IL-12) and IL-10 signaling, just
to name a few, have been identified as directly implicated with the disease.
Among the identified genes, 30 variants are specific for CD, 23 for UC, and the
remaining 110 were associated with the two phenotypes, indicating a high level
of overlap in the biological mechanisms involved [14]. Although common
variants can only explain 19% and 26% of the inheritability of UC and CD
respectively [19], the finding of low frequency or rare variants strongly associated
with chronic bowel inflammation, such as the X-linked inhibitor of apoptosis
(XIAP) [20], and the successful reproduction of some features of the disease in
genetically modified animal models [21], keep pointing out genetic susceptibility
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as one of the potential underlying conditions for IBD as they affect the host and
the interaction with microbial and environmental factors [22].
1.2.2.2 Dysregulated gut microbiota
Microbial cells in the gut exceed about 10 times the number of host cells
and can contain between 1000 and 5000 different species, among which
firmicutes, bacteroidetes, actinobacteria, and proteobacteria are recognized as
predominant [9]. The microbiota is a community that has co-evolved in a
homeostatic relationship with the host [22], and acts as an acquired functional
organ that contributes to the metabolism of indigestible nutrients, defense against
pathogens, angiogenesis, proliferation, differentiation of epithelial cells, pH, and
energy balance, and development and modulation of the mucosal immune
system [18]. Although there is no agreement on the definition of a healthy gut
microbiota, loss of the homeostatic equilibrium resulting from alterations in the
stability, diversity, and dynamics of this community can impact gut health and
triggers autoimmune disorders such as IBD [18]. Studies of the intestinal
microflora in IBD patients have shown decreases in firmicutes, bifidobacterium,
ruminococcaceae, and bacteroides, with concurrent increases in the pathogenic
consortium [23]. Some particular pathogens such as Escherichia coli,
Diplostreptococcus, Clostridium difficile, Fusobacterium necroporum, Shigella
sp., Helicobacter hepaticus, RNA viruses, Bacteroides vulgatus, and Yersinia sp.
have been suggested as potentially associated with UC [24]. Whether
dysregulated microbiota is a cause of the disease, or a consequence of other
7

physiological changes in the gut, and/or of the therapeutics used for
management of inflammation, is still a matter of debate [14], but the positive
results observed when using probiotics or performing transplantation of fecal
microbiota, have created a new potential strategy for the treatment of the disease
by pursuing the repopulation of the gut microbial community [23].
1.2.2.3 Disruption of the intestinal epithelial barrier
Intestinal epithelial cells (IECs) and non-epithelial cells constitute the
primary physical barrier against microbial cells and components of the luminal
content [18]. The adherent and tight junctions between IECs regulate the
selective penetration of nutrients, fluids, and microorganisms [9], and mucins and
antibacterial peptides form a mucus coating that confers an additional layer of
protection while allowing the exchange of molecules [18]. Impairment of the
mucosal barrier leads to an increase in intestinal permeability and facilitates the
free passage of microbes and their products across the intestinal membrane,
triggering the immune response, which is further exacerbated by mucosal
penetration of enteric pathogens and dysbiosis, marking the onset of the disease
[18,25]. Diarrhea, one of the most common clinical manifestations of the disease,
is the consequence of inappropriate expression or function of epithelial ion
transporters, that lead to electrolyte retention and accumulation of water in the
lumen [25]. The truncated function of the gene CDH1, which encodes for the
adherent junction E-cadherin, is one of the IBD susceptibility loci encountered by
genetic wide association studies [14] and has been found in intestinal biopsies
8

from CD patients, in which the protein presented a cytosolic localization [26], as
opposed to the membranous localization expected in healthy individuals .
Several variables affecting different components of the intestinal epithelial barrier
such as goblets cells loss, mucodepletion and mutation in mucin proteins [27],
degradation of E-cadherin by neutrophils elastase that contributes to tissue
damage [28], extensive apoptosis of IECs triggered by pro-inflammatory
mediators [29], altered expression and delocalization of tight junction proteins
[30], among others, have been found to be correlated with IBD.
1.2.2.4 Environmental factors
Environmental factors have a direct impact on the gut microbiota and the
immune system, and their differential contribution to IBD adds a substantial level
of complexity to understanding the disease. Several studies have tried to identify
potential patterns between exposure to environmental conditions and the
disease, but results are widely diverse and, in many cases, controversial.
According to a recent review by Ananthakrishnan et al. (2018) particulate matter
and other compounds present in air pollution can trigger the immune system
making the disease more common in urban centers. The use of medications can
trigger or perpetuate IBD, as antibiotics decrease the diversity of gut microbiota
creating dysbiosis, while non-steroidal anti-inflammatory drugs (NSAIDs) are
associated with gastric and duodenal ulcerations and increased mucosal
permeability [31]. Behavioral patterns such as stress, anxiety, depression,
impaired sleep, and excessive sanitization contribute to IBD, while smoking has a
9

controversial role as it seems to worsen CD by increasing the relapse rate, but
appears to be protective in UC, involving effects over the gut microbiota, mucosal
membrane integrity, and alteration in endothelial functions mediated by nitric
oxide [18].
1.2.3 Dysregulated immune response: the central role of cytokines in IBD
The intestinal immune response is the outcome of the interaction between
the immune cells, gut microbiota, and the intestinal epithelial barrier, shaped by
the contribution of environmental and genetic factors [18]. Transgression of the
epithelial barrier by microbial antigens activates mucosal immune cells and
triggers the release of pro-inflammatory signals, initiating the inflammatory
response. In healthy individuals, anti-inflammatory signals and tissue repair
mechanisms mediate the resolution of inflammation facilitating the recovery of
intestinal homeostasis. However, when the inflammatory response is aberrant, or
regulatory mechanisms fail, non-resolved inflammation becomes chronic [32].
This results in a large number of T cells, B cells, macrophages, neutrophils, and
dendritic cells infiltrating the lamina propria, producing high levels of proinflammatory cytokines and generating tissue damage [9].
Cytokines have a central role in the pathogenesis and development of IBD
as they: i) govern the initiation, evolution, and resolution of the inflammatory
response, ii) drive intestinal inflammation and associated symptoms, iii) regulate
systemic effects that contribute to extra-intestinal manifestations, and iv) are
involved in the progression of destructive forms of the disease such as the
10

development of colitis-associated CRC [32]. Depending on the nature of the
trigger, T helper cells (Th) help to polarize the response of other immune cells.
CD and UC differ in the subset of Th cells involved in the inflammatory response.
CD is characterized by a more inflammatory Th1/Th17 response in which IFN-γ,
IL-17, IL-21, and IL-22 are the main cytokines produced, while UC is
characterized by a Th2-like response that involves IL-13, IL-5, and the expansion
of natural killer T cells [33]. These cytokines to different extent mediate proinflammatory functions such as the neutrophils recruitment, release of matrix
metalloproteinases, and the upregulation of TNF-α, IL-1β, IL-6, and IL-8,
however, results of clinical trials using antibodies against IFN-γ [34], IL-17A [35],
and IL-13 [36], have been disappointing [32].
1.2.3.1 Crucial pro-inflammatory cytokines
The pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 are produced in large
amounts by dendritic cells and macrophages, activate the pro-inflammatory
pathway NF-κB, and participate in upstream and downstream events associated
with both forms of the disease [33]. They induce the secretion of chemokines,
which recruit leukocytes by activating integrin receptors, then maintaining a
constant supply of infiltrating immune cells in the site of inflammation [37]. These
cytokines are not only considered the most important markers of inflammation
[18], but also crucial players in the development of inflammation-related cancer
[38,39].
•

IL-1 family
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IL-1β and IL-18 belong to the IL-1 family and are produced as inactive
zymogens that require the cleavage and activation by the IL-1 converting enzyme
caspase-1 mediated by the inflammasomes, to act as pro-inflammatory signals
[40]. IL-1β promotes innate immune pathology by boosting the recruitment of
neutrophils and the activation of innate lymphoid cells, while IL-1 receptor
signaling in T cells is involved in the early accumulation and survival of
pathogenic CD4+ T cells in the colon [32]. Inhibition of the NLRP3 inflammasome
and blockade of caspase-1 has shown beneficial effects in several murine
models of colitis [41,42].
•

IL-6

IL-6 acts as a pro-inflammatory signal by activating multiple target cells such
as antigen presenting cells and T cells and inhibiting the apoptosis of T-cells.
Although response in a subset of CD patients has been observed by the
blockade of IL-6 signaling, its clinical application requires careful attention as IL-6
also has important homeostatic functions by promoting the proliferation and
expansion of IECs [32].
•

TNF-α

TNF-α is the most important cytokine mediating intestinal inflammation [43]. In
addition to innate immune cells, adipocytes, fibroblast and T cells from patients
with IBD produce considerable amounts of TNF-α [32]. The pleiotropic effect of
this cytokine involves the activation of macrophages and T cells which results in
increased production of IL-1β and IL-6, induction of apoptosis in IECs, and the
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production of matrix metalloproteinases, aggravating epithelial erosions, ulcers,
and having a detrimental effect on the intestinal epithelial barrier, promotion of
angiogenesis, and pro-coagulant factors [32,44]. The positive clinical
improvement and macroscopic healing observed upon TNF-α blockade by
specific antibodies, points out the crucial role of this cytokine in IBD and makes
anti-TNF-α biologics a cornerstone in the treatment of IBD [45].
1.2.4 The potential role of diet in IBD
Diet is considered one of the most important factors impacting gut health
and it is potentially one of the main environmental factors involved in IBD, as it
greatly affects gut microbiota and the mucosal immune system. Evidence
suggests an inverse association between being breastfed as an infant and the
incidence of CD and UC as an adult [46]. Breastfeeding has a strong and durable
effect on the composition of the microbial community of the infant, exerts a
protective effect by facilitating the transference of antimicrobial components, and
contributes to the development of tolerance to dietary and microbial antigens
[31]. Short-term consumption of diets composed entirely of plant or animal
products rapidly altered microbial communities, mirroring the characteristic
differences between carnivorous and herbivorous diets, particularly in microbial
functions associated with carbohydrates and protein fermentation [47]. Mice fed
a diet high in saturated milk-derived fat, imitating a “western diet”, not only
exhibited a microbial community with an increased proportion of Bacteroidetes
and decreased in Firmicutes, but promoted the bloom of a minor pathobiont
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component of the gut microbiota (Bilophila wadsworthia), which promoted a Th1mediated immune response and the development of colitis in IL-10 deficient mice
(IL-10-/-) [48]. Low fruit and vegetable intake, and high consumption of total
protein, fat, and refined sugar are more common among IBD patients [18,24].
Epidemiological studies demonstrate a higher prevalence of IBD in
developed nations, and an accelerated growing incidence in developing countries
acquiring a westernized culture [7]. Western diet is high in fat and refined
carbohydrates, low in fiber and plant polysaccharides, and incorporates a large
proportion of animal-derived foods as a source of protein, while in contrast, the
Asian diet is mainly plant-based, with soybean serving as one of the main
ingredients [49]. Soybean and soy-derived compounds such as saponins,
phytosterols, phosphatidylcholine, lectin, isoflavones, proteins, and peptides
have received increasing attention over the last decades due to the plethora of
bioactive properties that have been identified [50], particularly after the FDA
authorized a health claim about the reduction of coronary diseases linked to a
soy protein consumption of 25 g per day [50]. A recent study revealed that
replacement of animal protein by soy-pea protein in an “American diet” reduced
the severity of experimental IBD in animal models, and had a better impact than
replacing refined carbohydrates with polysaccharides, or changing the
polyunsaturated fatty acids ratio [51]. In similar approaches, reviewed by Juritsch
and Moreau, animal models of IBD have shown improvement in histological
changes and pro-inflammatory markers when using soy protein concentrates, or
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soy as the only source of protein in the diet [52]. However, the incorporation of
soybeans, soy-product, or soy protein in the diet needs careful consideration, as
certain subsets of the population may suffer from an adverse reaction to soy
components. For instance, soy is one of the triggers that contribute to food
protein-induced enterocolitis syndrome, a non-IgE mediated food allergic
disorder in infants [53]. Soybean is officially recognized as one of the foods that
account for most serious allergic reactions in the United States [54,55], with at
least 16 IgE-binding proteins, including glycinin, β-conglycinin, and Kunitz trypsin
inhibitor, that could be involved in clinical allergy [56]. Therefore, the study and
utilization of individual soy components could be a more ideal approach to take
advantage of those with potential beneficial biological activity over IBD.
The utilization of non-protein compounds naturally present in plant
materials in the context of IBD has also been widely explored and reviewed.
Anthocyanins, flavan-3-ols (green tea polyphenols), soy isoflavones (genistein,
daidzein, and equol), proanthocyanidins (oligonol, cocoa and apple extracts),
flavanones (hesperidin and naringenin), flavonones (quercetin, rutin, kaemferol,
and myricitrin), stilbenes (resveratrol, piceatannol), curcuminoids, and
hydroxycinamic acids, among other plant derived components have been tested
in animal models of IBD but with controversial results, as in some cases their
administration can induce improved outcomes, while in others lead to worsening
of symptoms or particular markers of the disease depending on the dose, mode
of administration, nature of the compound (crude extract, purified , enriched food
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matrix, whole food), and the particular mechanism used to induce bowel
inflammation in the animal model [117, 118].
1.2.5 Lunasin, a soybean peptide with potential activity against IBD
Lunasin is a soybean peptide that for the past 20 years has been
extensively investigated due to its high potential activity against diverse chronic
disorders as a result of its antioxidant, anti-inflammatory, and anticancer
properties [57]. The observed biological activity in mammalian cell lines and
animal models, has raised the interest on its amino acids sequence, its mode of
action, and the potential presence of the peptide in other plant sources.
Although initial studies characterized lunasin as a 43 amino acids peptide
with an expected mass of 5025.23 Da, recent investigations have reported an
additional asparagine residue at the C-terminal, conferring a final structure of 44
amino acids with a mass of 5139.25 Da [58]. The structure of lunasin contains
three well characterized regions that have been associated with its biological
activity (Figure 1.1): a polyaspartic acid tail that interacts with core histones H3
and H4 and affects their acetylation, a cell adhesion domain composed of
arginine-glycine-aspartic acid that mediates integrin signaling and cellular
internalization, and a chromatin binding region that contributes to the
immunomodulatory function [59]. It was recently suggested that a fourth region
11RKQLQGVN18

can be involved in transepithelial transport across the intestinal

wall via the paracellular route [60].
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In soybeans, lunasin is encoded within the 2S albumin GM2S-1 gene [61]
and has been found in concentrations ranging from 0.1 to 1.33 g/100g flour in
ancestral lines and modern cultivars [62]. Evaluation of commercially available
soybean derived products via immunoassays suggests that lunasin remains
present in soy flakes, soy protein isolates, concentrates and hydrolysates, tofu,
soymilk, and soymilk based products at levels ranging between µg to mg/100g
[62,63]. Several studies have reported the presence of lunasin in different
sources such as rye [64], oats [65], triticale [66], barley [67], wheat [68], Solanum
nigrum [69], quinoa [70], amaranth [71], millet [72], lupinus species [73] and other
sources. However, searches of transcriptome and DNA sequences databases,
chemical, and molecular approaches have failed to find regions encoding for the
peptide or a precursor protein [74,75], pointing out the question about the origin
of the reported peptides in these sources. An immunological approach revealed
that the peptide isolated from some cereals and seeds react with antibodies
specific for the N-terminal but not for the C-terminal sequence [76], suggesting
that lunasin-like peptides, but non-identical to the one found in soybeans, are
present in these plant materials. Several methods have been designed for the
isolation of lunasin using soybeans [77] and mostly defatted soy flour [58,63,78].
However, to date, there have been no attempts to identify or recover lunasin from
other byproducts of the soybean industry, such as okara and tofu whey, which
are produced in large quantities during soymilk and tofu manufacturing.
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1.2.6 Biological activity of lunasin
Several biological properties are attributed to lunasin. Among them, anticancer and anti-inflammatory properties have been the most widely investigated.
1.2.6.1 Anti-cancer properties
In cell cultures, lunasin was shown to prevent the malignant
transformation of mammalian cells induced by E1A-oncogene [79,80] and rasoncogene [81], as well as by the chemical carcinogens 7,12-dimethylbenz
[a]anthracene and 3-methylcholanthrene [82], acting as a chemopreventive
agent. Lunasin has been shown effective in reducing proliferation, inducing
cytotoxicity, reducing migratory as well as colony and tumor forming capacity in
diverse in vitro models of cancer including leukemia [83], colon [84–86], breast
[87], melanoma [88,89], and non-small cell lung cancer [90]. These
chemotherapeutic effects seem to be mainly mediated by the induction of cell
cycle arrest in the G1/S and G2/M phases caused by the upregulation of the p27
and p21 cyclin-dependent kinase inhibitors [83,84,86,90], and in some cases by
the promotion of apoptosis via the mitochondrial pathway [83,84], mediated by
PTEN [87], PARP [86], Bcl-2, Bax, and cytochrome C [85]. In non-small lung
cancer cells, cycle arrest was observed without inducing apoptosis but
accompanied by a reduction in phosphorylated Akt and the sequential
phosphorylation of the retinoblastoma protein [90]. The reduced invasive
potential is possibly associated with the altered expression of extracellular matrix
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and adhesion genes downregulating integrins α5, β2, and matrix
metalloproteinase 10 (MMP-10) [85].
In vivo, topical administration of lunasin reduced tumor incidence and
delayed the appearance of tumors by two weeks in a model of skin
tumorigenesis, by inhibiting histones H3 and H4 acetylation with the consequent
induction of apoptosis and cell cycle arrest [80]. Intraperitoneal injection of
lunasin decreased breast tumor incidence [91], and reduced tumor volume in
non-small cell lung cancer [90]. A study on melanoma reported that lunasin
induced the expression of differentiation markers and reduced the expression of
stemness factors in the subpopulation of cancer initiating cells, leading to a
reduction in the colony and oncosphere formation, as well as decreased tumor
growth and pulmonary colonization [88,89].
1.2.6.2 Anti-inflammatory properties
The role of chronic inflammation in different degenerative disorders has
raised the interest in lunasin as an anti-inflammatory agent. In terms of the
immune cells, research has been focused on the effect of the peptide over
macrophages in an inflammatory state. In lipopolysaccharide (LPS)-activated
murine RAW 264.7 macrophages and human THP-1 macrophages lunasin
attenuated the inflammatory response by reducing the release of the proinflammatory cytokines TNF-α, IL-6 and IL-1β, as well as nitric oxide (NO), and
prostaglandin E2 (PGE2). Attenuation was the result of reduced expression of
iNOS and COX-2, through the inhibition of the NF-κB signaling pathway by
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preventing the activation of phosphorylated Akt and the translocation of p50 and
p65 sub-units of NF- κB in the nucleus [78,92,93]. Further investigation revealed
that cellular uptake of lunasin is enhanced by inflammatory signals, and mediated
by endocytic mechanisms that involve macropinosomes, integrin signaling
(αVβ3), and clathrin-coated structures [94].
Investigation of the biological activity of lunasin from the perspective of
inflammation-related diseases is still incipient. In synovial fibroblast isolated from
patients with rheumatoid arthritis, lunasin inhibited cell proliferation, induced
apoptosis, reduced the production of IL-6, IL-8, and MMP-3, and suppressed NFκB [95]. In an in vitro model of osteoarthritis, lunasin enhanced the expression of
the tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2, and suppressed
expression of MMP-3 and MMP-13, protecting type II collagen from degradation
in IL-1β-stimulated chondrocytes, by attenuating JAK2/STAT1/IRF-1 pathway
activation [96]. Using a model of obesity-induced inflammation, Hsieh and
coworkers demonstrated that in high fat-diet fed mice intraperitoneal
administration of lunasin decreased serum levels of leptin and malondialdehyde,
and reduced levels of MCP-1, IL-1β, and TNF-α in peritoneal macrophage from
female mice, while in males it prevented spleen enlargement, inhibited IL-6 and
promoted IFN-γ and IL-2 production in the immune cells isolated from the spleen,
inducing Th1-type response [97]. In the context of asthma, lunasin administration
to an in vivo model of allergic airway inflammation reduced eosinophil infiltration,
goblet cell metaplasia, IL-4 production, and expression of the proinflammatory
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gene FIZZ1, while promoting the accumulation of regulatory T cells in the lung
[98].
1.2.6.3 Other biological properties
Lunasin also acts as an antioxidant. It inhibited linoleic acid oxidation as
well as the production of reactive oxygen species in LPS-induced murine
macrophages [99], and protected intestinal epithelial cell lines from oxidative
damage and the cytotoxic effect of chemical oxidants such as hydrogen peroxide
and tert-butylhydroperoxide [100], mainly acting as a free radical scavenger [70].
Other biological effects have been reported on cholesterol regulation, Alzheimer
like-neuropathology, bone regeneration, cataracts, and other cardiovascular and
central nervous systems conditions [57,61].
Some evidence suggests subtle differences in the biological activity of
lunasin chemically synthesized and the one isolated from natural sources.
Naturally occurring lunasin has higher colony formation inhibitory activity, [81],
and increased binding affinity for histone H4 than the synthetic peptide [58].
Differences in the induction of cell cycle arrest and apoptosis between similar
studies have been also associated with this difference in origin [59]. Interestingly,
lunasin from oat showed similar activity to synthetic lunasin [65], although
evidence indicates the absence of the peptide in cereals [74,76]. It is possible
that amino acid sequences of the peptide, also found in non-soybean sources,
are responsible for the biological activity observed, but structural differences

21

explain the decreased effect of the synthetic peptide when compared with the
soy derived lunasin.
1.2.7 Lunasin in the gastrointestinal tract
Table 1.1 summarizes in vivo models reported for the anticancer and antiinflammatory activity of lunasin. Despite multiple studies promoting the
incorporation of soybean products in the diet, as a source of lunasin, in vivo
models that support biological activity upon oral ingestion are scarce.
1.2.7.1 Protection of lunasin during gastrointestinal digestion
Lunasin is known to suffer a proteolytic breakdown in the gastrointestinal
tract. Exposure of purified lunasin from soybeans and synthetic lunasin to
simulated gastrointestinal fluid showed that the peptide was digested after two
minutes of exposure [101]. In this same study, evaluation of Bowman-Birk
inhibitor (BBI), a bioactive peptide also present in soybeans, indicated that this
peptide, in contrast, was resistant to digestion and conferred some protective
effect to lunasin when combined [101]. Another study demonstrated that 25% of
lunasin survived pepsin digestion after 3 h, and 6% of the peptide was still
detectable after 6 h of sequential digestion by pepsin-pancreatin when lunasin
was part of soy flour [83], suggesting that the food matrix exerted a protective
effect over the stability of the peptide during gastrointestinal digestion. Upon
these findings, more attention was paid to the interaction between lunasin, and
the protease inhibitors present in soybeans, BBI, and Kunitz trypsin inhibitor
(KTI). The complementary role of these protease inhibitors and lunasin, in cancer
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prevention, has been investigated. The study performed by Hsieh and coworkers
in an in vivo model of breast cancer showed that intraperitoneal injection of
soybean lunasin, but not BBI, reduced tumor incidence and size, and delayed
tumor generation, suggesting that lunasin was the bioactive cancer preventive
agent in Bowman-Birk Inhibitor concentrate (BBIC), a crude soybean extract
attributed with chemo-preventive properties [102]. In the same study, the
exposure of lunasin to pancreatin in the presence or absence of BBI or KTI
indicated that both exert a protective effect over lunasin. Our research group
reported that lunasin concentration, after pepsin-pancreatin hydrolysis of lunasin
enriched preparations, was significantly correlated with BBI and KTI
concentrations, and mutations in KTI isoforms can result in a lower protective
effect to the peptide [103].
Mice and rats were used as in vivo models to investigate the bioavailability
of lunasin when orally administered as part of a lunasin-enriched soy preparation,
demonstrating that 3 h after gavage 30% of the oral dose was absorbed and had
reached tissues such as the liver, kidneys, heart, brain, lungs, and prostate, in an
intact and bioactive state [102]. Although the presence of lunasin in cereals is
controversial, similar reports have found bioactive lunasin in the liver, kidney, and
blood of mice fed with lunasin-enriched barley [67] and rye [64], which could be
explained by the presence of BBI and KTI type inhibitors in cereals, legumes,
and grasses [104]. Lunasin was also found in the liver of rats fed with lunasin
enriched wheat [68]. In this study, the presence of the peptide was assumed as
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positive by matching the sequence KQLQGVNLTPCEKH. Interestingly this
peptide contains most of the fraction RKQLQGVN, which was identified years
later as involved in the paracellular transport of the peptide [60]. Lunasin found in
the plasma of healthy male subjects fed with 50 g of soy protein, indicating the
bioavailability of the soybean peptide in humans [105].
1.2.7.2 Bioactivity of lunasin digestion-derived peptides
Although degradation of lunasin by the gastrointestinal digestive enzymes
may represent a limitation for oral delivery, evidence suggests that lunasin
derived peptides may still exert a biological effect. The first hint was provided by
Cruz-Huerta and coworkers, who evaluated the antiproliferative effect of the
digestion product after gastric and duodenal digestion of lunasin, over the CRC
cell line HT-29, showing a significant decrease of viable cells [106]. In this study,
the digestion-derived peptides were identified and it was revealed that BBI can
exert a protective effect even after inactivation of its protease inhibitory activity
[106]. Further research reported that some of these fragments are resistant
against brush-border peptidases and decrease the viability of CRC cells [60],
retain free radical scavenging properties, have a protective effect over the
viability and oxidative status on murine macrophage under oxidative stress, as
well as reduce the production of nitric oxide in macrophages induced into a proinflammatory state [107]. Recent reports corroborated the anti-inflammatory and
anti-cancer activity of peptides derived from in vitro gastrointestinal digestion of
soybean proteins [108]. How the full set of bioactive properties of lunasin may be
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modified after the proteolytic environment of the gastrointestinal tract is still an
emerging topic of research, but the evidence reported so far supports the
possibility of lunasin derived peptides exerting, at least to some extent, antiinflammatory, antioxidant, and anti-cancer properties. Further research is
required, in vitro and in vivo, to identify the potential biological activity of lunasin
digestion-derived peptides.
1.2.7.3 Biological activity of lunasin in the gut
Investigation into the biological activity of lunasin has been largely focused
on extraintestinal diseases, hence little is known about its properties in the
gastrointestinal tract. So far, in vitro approaches in different CRC cell lines have
shown that the peptide can induce cell cycle arrest in the G2/M phase and
apoptosis by the mitochondrial pathway, downregulate the activation of
extracellular matrix and adhesion genes, reduce migratory capacity, inhibit the
activation of focal adhesion kinase, increase the expression of the inhibitor of
kappa B alpha, and hinder the tumorsphere-forming capacity [84–86,109].
Lunasin also protects intestinal epithelial cell cultures from chemically induced
oxidative damage [100]. In vivo models of metastatic CRC, generated by
intrasplenic implantation of colon cancer cells, showed that intraperitoneal but not
oral administration of lunasin, significantly abrogated metastasis to the liver,
reduced histone acetylation markers and proliferating cells nuclear antigen, and
potentiated the effect of the chemotherapeutic oxaliplatin by suppressing the
FAK/ERK/NF-kB pathway upon binding α5β1 integrins and internalization into the
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nucleus [109,110]. Although these results show a potential use of lunasin in the
context of CRC, none of them address the activity of lunasin in the colon.
Recently, an ex vivo approach using human intestinal biopsies from
healthy individuals showed that lunasin exerts an immunomodulatory effect in the
intestinal mucosa [111]. Exposure of the explants to lunasin induced the mRNA
expression of IL-1β, TNF-α, IL-17A, PGE2-COX2, IL-10, and TGFβ while
downregulating iNOS and p65 subunit from NF-κB. In contrast, lunasin
significantly inhibited the expression of IL-17A and IFNγ, tended to restore
PGE2-COX2 expression and increased IL-10 and TGFβ, when the explants were
exposed to the presence of LPS as a pro-inflammatory stimulus.
1.2.7.4 Prior Work
Lunasin protease inhibitor concentrate (LPIC) is a soybean-derived
combination of BBI, KTI, and lunasin that exhibited high chymotrypsin inhibitory
activity and strong suppression of mRNA levels of pro-inflammatory cytokines IL1β and IL-6 in activated human macrophages [112]. In our research group,
preliminary experiments using an in vivo model of relapsing UC treated with LPIC
indicated that the combination of compounds significantly decreased serum
levels of TNF-α, colonic levels of IL-6, IL-1β, iNOS, and markers of neutrophils
activity in the colon [113]. However, some adverse effects were observed such
as increased body weight loss, sustained higher levels of fecal occult blood, and
increased disease activity index associated with softer stool consistency and
presence of visible blood, indicating that the decrease in the pro-inflammatory
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markers was not reflected in the clinical manifestations of the disease. A similar
outcome was obtained following the same approach to study BG-4, a 4-kDa
peptide from bitter melon seeds that strongly reduced pro-inflammatory cytokines
and radical oxygen species in activated THP-1 cells [114]. Indeed, treatment
with BG-4 exacerbated rectal bleeding, body weight loss, neutrophils infiltration,
and induced significant colon shortening while still decreasing pro-inflammatory
cytokines [115]. BG-4 has been reported to exhibit trypsin inhibitory activity 8.6
times higher than KTI [116]. The fact that these two compounds exhibited similar
adverse effects that seemed proportional to their protease inhibitory activity
suggests that the utilization of preparations with high protease inhibitory activity
in the context of IBD may not be beneficial.

1.3 Hypothesis and objectives
Over the last two decades, the investigation of the biological activity of
lunasin in in vivo models has shown promising results. In vitro approaches using
different cell lines have allowed researchers to gain more insights into the
potential mechanisms of action triggered by the peptide. However, the
investigation of lunasin has been focused on diseases occurring outside the
gastrointestinal tract, with unknown results on whether dietary consumption of
lunasin might be beneficial for intervention of bowel diseases. Recent efforts
have been made to understand how gastrointestinal digestion might affect
lunasin and its biological properties. The possible outcomes of the interaction
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between the peptide and the intestinal mucosa in healthy and inflammatory
states needed to be investigated.
Therefore, the overall objective of this research was to investigate the
biological activity of lunasin against bowel related diseases in in vivo models. The
main hypothesis was that lunasin can exert anti-inflammatory properties in the
bowel and mitigate inflammation-related diseases. To test this hypothesis, two
different scenarios of IBD were considered: i) chronic inflammation associated
with genetic susceptibility, which results in the spontaneous development of the
disease, and ii) chronic inflammation triggered by external factors, that progress
into colitis-associated colorectal cancer. Attending to the possible variations in
biological activity between the synthetic and naturally occurring lunasin, this
study pursued the utilization of a purified form of the peptide, using a byproduct
of the soybean industry as starting material. Three specific objectives were
pursued:
The first objective was to design a process for the isolation of lunasin from
tofu whey. Tofu whey prepared at laboratory scale was used to establish the
isolation conditions. The combined use of ethanol, calcium, and acidification to
different pH were tested to obtain a solid fraction enriched in lunasin from the
whey. Preparative gel filtration chromatography was used for purification, and
composition of the mobile phase, injection volume, and preparation grade of the
chromatographic column were evaluated. The designed isolation process was
then applied to commercially produced tofu whey. The purity and identity of the
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final product were established using immunologic and chromatographic
techniques, and bioactivity was assessed in murine macrophages stimulated into
an inflammatory state.
The second objective was to evaluate the potential of lunasin isolated from
tofu whey to reduce inflammasome-related IBD. IL-10-/- mice were used as in
vivo model of spontaneous colitis. Manifestations of symptoms and proinflammatory markers in different sections of the small and large intestine were
assessed in mice left untreated, orally administered with lunasin, or treated with a
caspase inhibitor as a control for the blockade of the inflammasome. Human
macrophages were used in vitro to identify the potential mechanism by which
lunasin modulates the inflammasome.
The third objective was to evaluate the ability of lunasin to mitigate
chemically induced colitis-associated carcinogenesis. Dextran sulfate sodium
and azoxymethane were used to mimic relapsing cycles of inflammation and
induce colitis-associated CRC. Mice receiving placebo jelly or jelly containing
lunasin were monitored for clinical symptoms of the disease. Pro-inflammatory
markers, tumor burden, and histopathological assessment for inflammation and
dysplasia were evaluated in the colon.
The results of this study are expected to serve as evidence of the
biological activity of lunasin in the bowel, and to indicate its potential utilization to
lessen bowel-inflammation related diseases. In addition, further investigation

29

about the inclusion of lunasin as an active preventive and therapeutic agent in
the context of IBD and intestinal cancers.
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Appendix

Figure 1.1 Primary sequence of lunasin indicating the functional regions.
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Table 1.1 Summary of reported use of lunasin in in vivo models of cancer and inflammation
Source
(Purity)

Disease Model

Route of
administration

Dosage

Observed results

Ref.

Soybeans
(>99%)

Melanoma and
non-small cell
lung cancer

Intraperitoneal
injection

10 or 30 mg/kg
bw daily

Significant reduction of
tumor size over time.

[117]

Soybeans
(>99%)

Melanoma

Intraperitoneal
injection

30 mg/kg bw
daily

Soybeans
(>95%)

Metastatic
Melanoma

Intraperitoneal
injection

30 mg/kg bw
daily

Synthetic
(NR)

Skin
tumorigenesis

Topic

Soybeans
(>95%)

Metastatic
colorectal cancer

Intraperitoneal
injection vs. Oral
gavage

Soybeans
(>95%)

Non-small cell
lung cancer
(NSCLC)

Intraperitoneal
injection

Significant reduction of
tumor size and weight,
and delayed detection of
palpable tumors
Reduced number of
macro-metastatic
outgrowths, and lower
area of micrometastatic
lesions to the lungs

[88]

[89]

2.5, 25 and 250
The highest dose reduced
µg/week
skin tumor incidence and
dissolved in
[80]
delayed the appearance
ethanol twice a
of tumors.
week
Intraperitoneal: 4
Significant reduction of
mg/kg daily.
metastasis to the liver by
[110]
Oral: 8 and 20
IP but not by oral
mg/kg bw daily
administration.
30 mg/kg bw
daily

Significant reduction of
tumor size over time.

[90]

53

Table 1.1 Continued
Source
(Purity)

Disease Model

Route of
administration

Soybeans
(>90%)

Metastatic
colorectal cancer

Intraperitoneal
injection

4 mg/kg bw alone
Inhibition of metastasis to
daily or with
the liver and potentiated
oxaliplatin twice a
effect of oxaliplatin
week

[109]

Aqueous
extraction of
soy protein
concentrate
(0.23% w/w)

Breast cancer

Oral via diet

0.15% or 0.23% Non-significant reduction
lunasin in the diet in tumor incidence in high+ 0.6% BBI
dose diet only.

[91]

Synthetic
(No Report)

Breast cancer

Intraperitoneal
injection

4 and 20 mg/kw
bw three times a
week

Synthetic
(>95%)

Obesity-induced
inflammation

Intraperitoneal
injection

20 mg/kg bw
daily

Synthetic
(>95%)

Asthma

Intranasal

20 µg/mouse on
specific days

Dosage

Observed results

Ref.

Equal decreased tumor
incidence with the two
[102]
doses.
Females: reduced IL-1β,
TNF-α, MCP-1, serum
leptin, and
malondialdehyde.
[97]
Males: Inhibition of spleen
enlargement and IL-6,
promotion of IL-2 and INFγ.
Reduced cells infiltration,
goblet cell metaplasia and
[98]
IL-4 production, increased
regulatory T cells
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CHAPTER 2. UTILIZATION OF TOFU PROCESSING
WASTEWATER AS A SOURCE OF THE BIOACTIVE PEPTIDE
LUNASIN
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2.1 Abstract
Tofu whey is a waste byproduct generated in large quantities during tofu
manufacturing. Lunasin is a naturally occurring peptide present in soybeans with
biological properties of remarkable interest for human health. A simple and
feasible method to isolate bioactive lunasin from tofu whey wastewater was
designed. A combination of alcoholic precipitation of high-molecular weight
proteins from the whey, isoelectric precipitation of lunasin enriched material, and
purification via gel filtration chromatography was selected as the best approach
using tofu whey prepared at the laboratory scale. This process was applied to
tofu whey produced by a local tofu factory and 773 mg of 80% purity lunasin was
obtained per kg of dry tofu whey. Significant reduction of nitric oxide, and proinflammatory cytokines TNF-α and IL-6 over lipopolysaccharide activated murine
macrophages confirm its biological activity. Our three-step process is not only
simpler and faster than the previously reported methods to obtain lunasin but
provides a sustainable approach for the valorization of a waste product,
promoting the better utilization of soybean nutrients and active compounds.

2.2 Introduction
Tofu is a cheese-like product obtained from soybeans. Lactose
intolerance, celiac disease, increased health awareness and interest in
vegetarian and vegan lifestyles have positioned tofu as a globally growing market
[1]. Tofu production involves the grinding of hydrated soybeans to obtain soymilk,
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which is then coagulated to form the tofu curd. During the process, two waste byproducts are obtained in large quantities: okara and tofu whey. Tofu whey is the
liquid waste fraction that remains after the curd formation and pressing [2]. About
9 kg of whey, containing up to 1% carbohydrates, 1% fats, 0.8% proteins, and
0.4% minerals, are produced per kg of soybeans used to make tofu [3]. Recovery
of nutrients and bioactive compounds, transformation into functional and
alcoholic beverages, and utilization as a growth media for the propagation of
biomass are the most commonly studied applications of this by-product [2,3].
However, whey continues being mostly discarded into the sewage or soil, posing
an environmental threat due to its high biological and chemical oxygen demand
(BOD: 6000 – 8000 mg/L; COD: 7,500 – 26,000 mg/L) [3].
Lunasin is a 5 kDa soy-derived peptide that has raised interest in its
potential application as a dietary supplement for the prevention of several chronic
and degenerative diseases. This is due to the increasing body of evidence that
supports its chemopreventive, anti-inflammatory, antioxidant, anti-hypertensive,
cholesterol-regulating, neuroprotective and immunomodulatory properties [4].
The ability of lunasin to inhibit tumor growth and invasiveness of cancer cells has
been demonstrated in vitro and in vivo for melanoma, breast, lung, and colorectal
cancer [5], while the anti-inflammatory potential have been mostly studied in vitro
and is associated with the reduction of pro-inflammatory molecules such as nitric
oxide (NO), TNF-α and PGE2 [6]. Most of these properties seem to be modulated
at the epigenetic level by particular amino acid sequences present in the lunasin
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structure: a polyaspartic acid tail that can inhibit acetylation of core histones H3
and H4, an RGD domain that modulate integrin signaling and mediates cellular
internalization, and a chromatin-binding region that provides immunomodulatory
functions [7].
The high cost associated with the utilization of synthetic lunasin has led to
the formulation of several approaches to isolate the peptide from natural sources.
Krishnan and coworkers developed a simple procedure to isolate a protein
fraction from soybeans highly enriched in lunasin, Bowman Birk inhibitor and
Kunitz Trypsin inhibitor via aqueous ethanol extraction and calcium precipitation
[8]. The three peptides combined account for 60% of the total protein content in
the final product based on densitometric analysis, or up to 80% if anionexchange chromatography is used for further purification. Seber et al. designed a
six-step isolation process involving PBS extraction, ionic exchange
chromatography (IEC), treatment with a reducing agent, ultrafiltration, reverse
phase chromatography, and ultrafiltration, using defatted soy white flakes as
starting material and yielding a product with >99% purity based on densitometric
analysis [9]. The purity reported for these isolation techniques indicate the
relative abundance of the active peptide only as a ratio to other peptides and
proteins that are revealed during the electrophoretic separation, while the
presence of other non-peptide components in the final product was not
considered. Dia et al. developed a four-steps process that involved aqueous
extraction of defatted soy flour, IEC, ultrafiltration, and gel filtration
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chromatography achieving 80% purity of lunasin in the final product as assayed
via HPLC [10]. These methods are complicated and costly, as they deal with the
complete and complex protein composition of soybeans.
Lunasin has been found in several commercially available soybean
products, including soymilk and tofu [11,12]. Then it is reasonable to hypothesize
that tofu by-products, may contain remaining fractions of lunasin and can serve
as alternative sources of the bioactive peptide. So far, there have been no
attempts to identify or isolate lunasin from soymilk or tofu waste by-products. Our
objective was to design a simple and feasible method to isolate lunasin from tofu
whey wastewater. In addition, the in vitro anti-inflammatory properties of lunasin
were assessed to corroborate that the isolated lunasin maintains its bioactive
properties.

2.3 Materials and Methods
2.3.1 Materials
Non-GMO soybeans (Newest Crop) and food-grade calcium sulfate tofu
coagulant (Terra Alba) were obtained from Soymerica. Industrially produced tofu
whey was kindly provided by a local tofu manufacturer located in Summertown,
TN, USA. Lunasin polyclonal antibody was raised in rabbits using the 15 amino
acid sequence corresponding to the C-terminus of lunasin and was produced by
ProteinTech Group (Chicago, IL). Lunasin standard was synthesized by LifeTein
LLC (Somerset, NJ), soybean Kunitz trypsin inhibitor (KTI) and Bowman-Birk
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inhibitor (BBI) standards were from VWR International LLC (Atlanta, GA) and
Sigma-Aldrich Corp. (St. Louis, MO), respectively. SDS-PAGE and Western blot
gels, membrane transfer kits, reagents, and goat-antirabbit secondary antibody
were obtained from Bio-Rad Laboratories (Hercules, CA). All other chemical and
biological substances were purchased from VWR International, Sigma-Aldrich,
and Thermo Fisher Scientific unless otherwise specified.
2.3.2 Laboratory scale preparation of tofu whey
Tofu whey was prepared at the laboratory scale and used to design the
isolation method. Briefly, 100 g of soybeans were soaked overnight. Excess
water was drained, and fresh water added to a final ratio of 1:9 dry beans: water.
The mixture was blended for 3 min and the solid fiber (okara) was separated
from the liquid fraction (soymilk) using a cheesecloth. Soymilk was boiled for 10
min, allowed to cool down to 70°C, and 3 g of calcium sulfate suspended in water
were added to promote formation of tofu curd. Tofu was separated from the whey
by applying a constant pressure of about 1360 Pa over the curd using a regular
kitchen tofu press until dripping of the whey stopped.
2.3.3 Lunasin enrichment
Different volumes of ethanol were added to the whey to reach a final
concentration of 20, 30, 40, or 50% ethanol v/v. Samples were stirred for 10 min,
centrifuged at 15,800 g for 15 min, and precipitates and supernatants were used
to identify the effect of increasing concentrations of ethanol in the protein profile
and the presence of lunasin in the soluble and non-soluble fractions. Treatment
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of the whey using a final concentration of 30% v/v ethanol was chosen for further
analysis. To induce the precipitation of soluble proteins, the alcoholic
supernatant, after centrifugation, was adjusted to pH 4.5, 5.5 or calcium chloride
was added to a final concentration of 20 mM. Samples were centrifuged and the
precipitates were freeze dried, pulverized using mortar and pestle, and used to
identify the effect of the three precipitation techniques over the protein profile and
the presence of lunasin. Bioactivity of the three final pre-enriched products was
assessed by evaluating anti-inflammatory properties.
2.3.4 Adjustment of preparative gel filtration chromatography parameters
Preparative gel filtration chromatography was used for final purification of
lunasin. Evaluation of the chromatographic parameters was performed using an
ÄKTA pure protein purification system (GE Healthcare Life Sciences,
Piscataway, NJ) equipped with sample pump and UV-detector (280 nm).The
following chromatographic parameters were evaluated: i) composition of the
mobile phase, 20 mM Tris-HCl buffer + 0.15 M NaCl, pH 7.6 vs. 100 mM
ammonium bicarbonate (NH4HCO3), pH 7.8, ii) porosity of the packed bed in the
chromatographic column, also referred as preparation grade (pg), pg 30 vs. pg
75, and iii) volume of sample injected, 0.5 mL vs. 3 mL. A HiLoad 16/600
Superdex column containing the indicated packed bed (30 or 75 pg) was
equilibrated with 3.0 column volumes (CV) of the indicated mobile phase (TrisHCl or NH4HCO3). Laboratory prepared whey was freeze dried and resuspended
in the appropriate mobile phase at a concentration of 120 mg/mL. The indicated
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sample volume (0.5 or 3 mL) was injected in the column. Elution was performed
using 3.0 CV of the appropriate mobile phase at 1 mL/min. Ten-mL fractions
were collected during the elution phase and analyzed for protein, lunasin and
total carbohydrate contents, and optical density at 400 nm. Base conditions were
established performing a chromatographic run using NH4HCO3 mobile phase,
30pg column and 0.5 mL of sample injection.
2.3.5 Isolation of lunasin from industrially produced tofu whey.
Industrially produced tofu whey was collected and frozen for up to one
month, at -80 °C until use. After thawing at room temperature, suspended solids
were removed using a cheese cloth. The whey was divided into three fractions:
the first fraction was freeze-dried, the second was spray-dried using a BuchiB290 Mini Spray dryer (BÜCHI Corporation, Switzerland) at 40% pump flow rate
and 170°C inlet temperature, and the third fraction was treated with our designed
lunasin enrichment method described in Section 2.3.3 Briefly, ethanol was added
to the whey to a final concentration of 30% v/v, followed by stirring and
centrifugation as described above. The supernatant was adjusted to pH 4.5 and
after centrifugation, the precipitate was freeze-dried overnight. Approximately 2.0
mg ± 0.1 of dry lunasin enriched material was obtained per mL of industrial whey.
Spray-dried whey (SDW), freeze-dried whey (SDW) and lunasin enriched
material were used for chromatographic purification. This approach allowed the
comparison of our designed lunasin enrichment method with conventional hot
(spray drying) and cold (freeze-drying) drying mechanisms. To inject samples
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with equivalent protein content 120 mg/mL of SDW or FW, or 60 mg/mL of
lunasin enriched material were resuspended in 100 mM NH4HCO3 by vortexing
horizontally for 15 min. After centrifugation at 30,000 g, the supernatant was
filtered, and 3 mL were injected in a HiLoad 16/600 75 pg Superdex column.
Elution was performed as described above using 100 mM NH4HCO3. Aliquots of
the collected fractions were analyzed for lunasin, optical density at 400 nm, and
carbohydrates content. Fractions containing a significant amount of lunasin were
placed in a shaking water bath, brought to 40 °C for 5 min to remove any
remaining NH4HCO3 and then freeze-dried.
2.3.6 Analytical methods for the characterization of lunasin
2.3.6.1 SDS-PAGE and Immunoblotting
Samples were denatured and reduced in the presence of sodium dodecyl
sulfate and β-mercaptoethanol in boiling water for 5 min and electrophoretic
separation was performed at 400 mA for 35 min in a Mini-PROTEAN tetra
vertical electrophoresis cell (Bio-Rad). The gel was stained with Coomassie Blue
G-250 for 1 h, destained with water, and imaged using a ChemiDoc Touch
Imaging System (Bio-Rad). For immunoblotting, non-fixed gels after SDS-PAGE
were transferred to PVDF-membranes using a Trans-Blot Turbo transfer system
(Bio-Rad), blocked with 5% non-fat dry milk in 0.01% tween 20 Tris-buffered
saline (TBST) for 1 h at room temperature. The membrane was incubated with
1:1000 lunasin, soybean KTI or BBI [13] primary antibodies raised in rabbits for
1.5 h at room temperature. After three 10-min washing with TBST, goat-antirabbit
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secondary antibody was added and incubated for 2 h at room temperature,
followed by another cycle of TBST washings. Immunoreactive bands were
visualized via chemiluminescence in a C-Digit Blot scanner (LI-COR Biosciences,
Lincoln, NE) using Image StudioTM software.
2.3.6.2 Enzyme-linked immunosorbent assay (ELISA)
Lunasin content in gel filtration liquid fractions and enriched precipitates
were estimated via ELISA as previously described [10] with slight modifications:
the plate was blocked with 5% bovine serum albumin in 0.5% Tween 20
phosphate-buffered saline, and incubation times with primary and secondary
antibodies was 1 h each.
2.3.6.3 High performance liquid chromatography
Molecular weight profile via size exclusion chromatography was analyzed
as previously described [14]. For determination of lunasin in purified fractions, 20
µL of the sample was injected into an Agilent (Folsom, CA) 1200 HPLC system
equipped with an Eclipse Plus C18 column (4.26 x 250 mm, 5 µm), and diode
array detector (215 nm). Elution was performed with acetonitrile (buffer A) and
0.1% trifluoroacetic acid in water (buffer B) as follows: step elution starting at
10% buffer A, with 10% increments up to 50%, holding each condition for 5 min,
followed by equilibration of the column with 10% buffer A for 3 min. Quantification
of isoflavones was performed according to previously reported protocol [15] by
injecting 20 µL of the sample in the same column and equipment used for
lunasin.
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2.3.6.4 Total carbohydrates, protein content and trypsin inhibitory activity
Total carbohydrates were measured in gel filtration chromatography
fractions via phenol-sulfuric acid method as described previously [16]; glucose (0
– 0.5 mg/ml) was used as standard. For gel filtration chromatography fractions,
the relative protein content was estimated in µg/mL as A 280nm/ε, where ε is the
mass attenuation coefficient for the whey, calculated as 0.018 by measuring the
absorbance of different dilutions of tofu whey from a stock solution with known
protein content. Protein content by Bradford assay and trypsin inhibitory activity
using N-α-benzoyl-D, L-arginine 4-nitroanilide substrate were measured as
previously described [14].
2.3.6.5 Matrix-assisted laser desorption ionization time-of-flight mass
spectrometry (MALDI-TOF-MS) analysis.
The 5 kDa protein band was excised from Coomassie-stained SDS-PAGE
gel for the identification of lunasin via MALDI-TOF-MS as previously described
[17].
2.3.7 Biological activity of the isolated lunasin
RAW 264.7 murine macrophages (ATCC, Manassas, VA) were cultured,
treated and analyzed as previously described [18]. Cells were seeded at 5x103
cells/well in a 96-well plate, allowed to attach overnight, and then treated with
lunasin at the indicated concentrations, in the presence of lipopolysaccharide
(LPS), for 24 h. Supernatants were collected for analysis of pro-inflammatory
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cytokines IL-6 and TNF-α by ELISA (BioLegend, San Diego, CA) and nitric oxide
(NO) production by Griess reagent assay. MTS assay (Promega, Madison, WI)
was used to test cell viability, according to the manufacturer’s protocol.
2.3.8 Statistical analysis
Results are reported as mean ± standard deviation for at least three
replicates. Data were analyzed for significant differences (p-value <0.05) via
ANOVA followed by Tukey posthoc test, using Statgraphics Centurion ® software
(Statgraphics Inc, The Plains, VA).

2.4 Results and Discussion
The yield of soymilk, tofu, okara, and whey for the laboratory-produced
tofu are presented in Table 2.1 In okara, the presence of soluble proteins is
derived from the fractions of soymilk retained in the solid fiber which can be
considered as a potential source of the peptide. On the other hand, upon addition
of calcium sulfate to soymilk, high molecular weight proteins belonging to the 11S
(glycinin) and 7S (β-conglycinin) fractions aggregate forming the curd, while the
low molecular weight proteins (< 16 kDa) remain soluble in the whey [19]. It could
then be expected that the 5 kDa lunasin is present in the whey. Preliminary
experiments using the whey and an alkaline extract from okara indicated that the
amount of lunasin available in the whey is about 45 times higher than in okara
(Supplementary Table 2.1), making it a better candidate for further exploration as
a source of lunasin.
67

2.4.1 Lunasin enrichment from tofu whey
2.4.1.1 Alcoholic precipitation of high-molecular weight proteins
The purification of proteins via precipitation with alcohols has been
reported and it has been shown that methanol and ethanol were capable of
producing precipitates with retained enzymatic activity [20,21]. Ethanol has been
successfully used to induce the aggregation of particular protein fractions from
soybean preparations with bioactive properties [8,22]. We evaluated the effect of
different concentrations of ethanol (20, 30, 40, and 50% v/v) on the proteins
present in tofu whey. Electrophoretic separation (Figure 2.1A) indicated that upon
increasing concentrations of ethanol, proteins with higher molecular weights were
preferentially precipitated. At 20% v/v there was no apparent variation in the
distribution of soluble proteins, while at 30% most of proteins higher than 30kDa
were almost depleted. At 40 and 50%, proteins smaller than 25 kDa remained in
the supernatant. Figure 2.1B presents the size exclusion chromatographic profile
of the supernatants. Retention times and molecular weight of chromatographic
standards are presented in Supplementary Table 2.2. As it can be observed,
proteins with retention time lower than 6 min, corresponding to molecular weights
higher than 6.5 kDa, were a predominant group in the whey. Variations in the
profile corroborated the preferential impact of ethanol over this subset of proteins
in the whey. At a concentration of 20% the height of peaks associated with high
molecular weight proteins was reduced and became comparable to the height of
peaks associated with peptides with retention times between 6 and 8 min,
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corresponding to molecular weights between 1 and 6.5 kDa. At higher
concentration of alcohol, the peptides fraction became the predominant group in
the supernatant. It is known that the addition of miscible organic solvents
increases intra- and intermolecular electrostatic forces that lead to variations in
the folding of the protein molecules [23]. It is feasible that in complex proteins,
with higher molecular weight, augmented repulsive intramolecular interactions
lead to the exposure of buried ionic and polar groups. These available groups
could participate in attractive protein-protein interactions with the exposed
oppositely charged groups resulting in aggregation.
Western blot analysis (Figure 2.1C) revealed that fractions of lunasin
progressively precipitated as the concentration of ethanol increased. Although
variations in intramolecular electrostatic interactions may not have a considerable
effect over the intrinsically disordered structure of lunasin [24], the dense
negative charge of the polyaspartic acid tail could participate in peptide-protein
interactions with the exposed positively charged side chains from the partially
unfolded structures of larger proteins. This could lead to partial co-precipitation of
lunasin with high molecular weight proteins. At 20%, in addition to the 5 kDa
lunasin, an immunoreactive band located around 14 kDa is present. Seber and
coworkers reported a 14 kDa complex originated between lunasin and a 9 kDa
peptide via disulfide bridges [9]. However, the reducing nature of our
electrophoretic separation, mediated by β-mercaptoethanol, and side test using
dithiothreitol suggested that the complex present in the whey is not formed by
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disulfide bonds. The 30% ethanol was the lower concentration at which
precipitation of most high molecular weight proteins occurred, including the 14
kDa complex, with a minor effect over the solubility of lunasin. Hence, this
concentration of ethanol was selected for the pre-enrichment process.
The characterization of the precipitate induced by ethanol treatment
indicated that this by-product contained between three and seven times more
protein, nine to fourteen times more lunasin, and comparable biological activity to
some commercially available lunasin enriched dietary supplements
(Supplementary Table 2.3 and Supplementary Figure 2.1), suggesting that it
could be explored as a product with potential market value.
2.4.1.2. Precipitation of lunasin enriched material
Isoelectric precipitation at pH 4.5, 5.5 or precipitation mediated by calcium
were tested as potential mechanisms to recover lunasin from the alcoholic whey
after removal of high-molecular weight proteins. Table 2.2 presents the
characterization of the obtained lunasin enriched fractions. Calcium has been
previously used as a tool for the fractionated precipitation of seed storage
proteins present in soybeans, peanut, beans, peas, and alfalfa [17]. In aqueous
solutions, calcium forms strong complexes with the carboxylic groups of aspartic
acid and glutamic acid [25]. As lunasin contains nine consecutive aspartates at
the carboxylic end, and two glutamic acids present in the structure [7], we
expected that addition of calcium would lead to the formation of complexes with
lunasin mediated by the interaction of the divalent cation mostly with the
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polyaspartic acid tail. However, the significantly lower lunasin content in calcium
precipitate in contrast to the isoelectric precipitates, indicated a low efficiency of
lunasin complexation. Electrophoretic profile (Figure 2.2A) shows strong bands in
the calcium precipitate that could correspond to the acid and basic fractions of
glycinin (32 and 20 kDa respectively) and to the β and α subunits of β-conglycinin
(52 and 68 kDa respectively). It has been shown that glycinin and β-conglycinin
precipitate at a minimum calcium concentration of 0.4 mM and 1.4 mM,
respectively [26]; then it is possible that calcium favored the precipitation of these
two fractions, over lunasin complexation. The presence of peaks at retention
times later than 10 min (Figure 2.2B), suggested the presence of compounds
with molecular weight smaller than 75 Da, which may correspond to organic salts
probably formed with the divalent cation. In addition, the significantly lower
protein content corroborated that calcium preferentially induced precipitation of
non-protein compounds, present mostly in the precipitate.
Isoelectric precipitation is one of the most used mechanisms to isolate
proteins. While precipitation at pH 4.5 has been shown to provide the highest
yields during the production of soy protein isolates [27], two-dimensional
electrophoresis of an extracted fraction, from defatted soy flakes, enriched in
lunasin exhibited a 5 kDa band at pH of 5.5 [28], suggesting this particular pH as
a more specific isoelectric point for the peptide. No significant differences were
found for any of the parameters quantified for the two isoelectric precipitates. A
stronger band at 32 kDa in the pH 4.5 precipitate indicated a higher impact over
71

the acid glycinin fraction, while pH 5.5 had a higher effect over the β subunit of βconglycinin (52 kDa) (Figure 2.2A). These observations agreed with the
molecular weight distribution exhibited in the chromatographic profiles.
Immunoblotting revealed that not only lunasin, but the 14 kDa complex, as well
as Kunitz (KTI) and Bowman-Birk (BBI) inhibitors, were present in all the
precipitates (Figure 2.2C). No detectable trypsin inhibitory activity in any of the
three precipitates (Table 2.2) indicated that the protease inhibitors were present
as inactive molecules. The boiling of the soymilk before the curd coagulation led
to the irreversible denaturation of the active sites required for the inhibitory
activity.
Soybeans are known to contain several biologically active compounds.
Among them, isoflavones have gained great recognition due to their ability to
have a preventive effect over several diseases such as type II diabetes,
osteoporosis, cardiovascular diseases, and hormone-associated cancers [29]. As
they have been reported to be present in tofu whey [30], we tested for the
presence of the major soy isoflavones in the precipitates. As expected, none of
the aglycone forms was detectable while the more water-soluble glucosides
daidzin and genistin were both present (Table 2.2). To ensure that the biological
activity was conserved, the anti-inflammatory properties of the precipitates was
assessed by measuring their ability to reduce the level of nitric oxide produced by
activated murine macrophages. A significant dose-dependent decrease of nitric
oxide released into the media was observed (Figure 2.2E), with no effect over the
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proliferation of the immune cells (Figure 2.2D), suggesting that the biological
activity was still present.
During storage at 23 °C and 51% relative humidity, the pH 5.5 precipitate
discolored brown and became highly hygroscopic, while pH 4.5 powder
maintained its original characteristics as a white homogeneous dry powder.
Considering that lunasin enriched material at pH 4.5 has higher lunasin and
protein content than calcium precipitate, and apparent better storage stability
than the product at pH 5.5, isoelectric precipitation of the alcoholic whey at pH
4.5 was selected for the preparation of the lunasin enriched material.
2.4.2 Adjustment of preparative gel filtration chromatography parameters
Since the presence of proteins of different sizes continued to be an
interference in the lunasin enriched material, a size-based separation approach
can be used for lunasin purification. Gel filtration chromatography has been
widely applied for the fractionation and purification of protein, peptides, enzymes
and DNA based on their size and geometry while maintaining their biological
activity [31,32]. To establish the most appropriate chromatographic conditions
for the separation of lunasin from tofu whey, the effects of mobile phase
composition, volume of sample injected, and the porosity of the packed bed
(preparation grade-pg) were evaluated., The baseline was established by
injecting 0.5 mL of sample, prepared as described in the experimental section, in
a 30 pg column using 20 mM Tris-HCl + 0.15 M NaCl pH 7.6 as mobile phase.
Modifications in the characteristic profiles were evaluated using alternative
73

conditions (Figure 2.3): 100mM NH4HCO3 pH 7.8 as mobile phase, a 75 pg
column, or injecting 3 ml of the sample.
2.4.2.1 Effect of mobile phase (non-volatile vs. volatile)
During preliminary experiments using the base conditions, we observed
that buffering salts in the mobile phase became the major component of the final
product after freeze drying, making the content of lunasin negligible. Desalting
trials using macrosep advance centrifugal device 1K MWCO allowed removing
98% of the salts present, though, the remaining salt continued to be 10 times
higher than lunasin in the final dry product. So far, only one report has clearly
stated the performance of concentration and buffer exchange steps, via
ultrafiltration, after the final chromatographic purification [9]. To address this
issue, we proposed the use of a volatile buffer as mobile phase. Upon mild
heating, NH4HCO3 easily decomposes into the volatile compounds ammonia and
carbon dioxide, [33]. Preliminary tests indicated that after heating 100 mM
NH4HCO3 at 40°C for 5 min no solid residue remained. Then we performed the
gel filtration chromatography using 100 mM NH4HCO3 pH 7.8 as mobile phase.
Under base conditions, using Tris-HCl buffer, lunasin eluted at 60 min and the
resolution of the peaks (Figure 2.3A) and carbohydrates profile (Figure 2.3B)
suggested a good level of separation of the peptide from other compounds
present in the whey. Figures 2.3A and 2.3C show that the chromatographic
profile, as well as retention times for lunasin and carbohydrates using ammonium
bicarbonate, resemble those obtained with Tris-HCl buffer. The fact that no shift
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in the retention time of any peaks was observed, indicated that nonspecific ionic
interactions between tofu whey components and the packed bed were negligible,
and the presence of strong ionic salts in the mobile phase, such as NaCl, was
not required. Then we concluded that NH4HCO3 was a more suitable mobile
phase than Tris-HCl for the chromatographic separation and recovery of lunasin
from tofu whey.
2.4.2.2 Column preparation grade (30 pg vs. 75 pg)
Preparation grade (pg) refers to the grade of fractionation or separation
that the column can achieve in relation to the relative molecular mass (Mr) of the
compounds present in the sample [34]. In the 30 pg column (Mr < 10,000)
probably all proteins in the range of 10 to 75 kDa traveled externally to the
packing beads, leaving the column as a whole group represented by a wide peak
with retention times between 40 and 50 min (Figure 2.3A). In the 75 pg column
(3,000 < Mr < 70,000), a better resolution of the proteins and peptides was
observed, accompanied by a shift in the retention time of lunasin peak to 88 min,
28 min later than the 30 pg column. Analysis of the relative amounts of lunasin
and proteins (Figure 2.3D) showed that most of the compounds absorbing at 280
nm eluted at around 108 min, 20 min later than lunasin, while lunasin containing
fractions exhibited a minimum content of proteins. The better resolution of the
peaks achieved by the 75 pg column made it more suitable than the 30 pg
column for purification of lunasin.
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2.4.2.3 Injection volume of the sample (0.5 vs. 3 mL)
Sample volume plays a decisive role in the resolution of chromatogram
peaks, as larger volumes result in peak broadening; thus a sample volume no
larger than 4% CV is recommended for high resolution fractionation [34]. For a
75 pg XK16 column with CV = 120 mL, 0.5 mL sample volume (0.4% of the CV)
showed a good resolution for lunasin peak (Figure 2.3A); however, the amount of
dry lunasin recovered per run was negligible. Figures 2.3A and 2.3E show the
impact of a 6-fold increase in the sample injection volume (3 mL, equivalent to
2.5% of the CV). As expected, lunasin recovered in the fractions increased
proportionally, accompanied by a remarkable widening of the peak, which now
goes from 58 to 88 min. The consequent decrease in the resolution led to the
overlapping of lunasin to adjacent peaks associated with larger and smaller
molecules.
The four fractions exhibiting relevant content of lunasin, corresponding to
retention times 58, 68, 78, and 88 min were further analyzed. Electrophoretic
separation (Figure 2.3F) showed the progressive and significant reduction of
high-molecular weight proteins in the fractions: eluate collected at 58 min
contained proteins between 15 and about 60 kDa while eluate at 88 min was free
from proteins above 15 kDa. Immunoblotting (Figure 2.3G) indicated that while
the two earlier fractions contained only the 14 kDa complex, fractions at 78 and
88 min contained mostly the 5 kDa peptide. Molecular weight distribution (Figure
2.3H) revealed that the 88 min fraction contained the main peak at 7.2 min,
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corresponding to 5 kDa lunasin, while for fraction at 78 min this peak was
combined with a larger one at 7.0 min, probably associated with the 14 kDa
complex. The difference in retention times during HPLC size exclusion
chromatography profiling observed for the isolated lunasin (7.2 min) and the
synthetic lunasin standard (6.6 min) could be a result of differences in the folding
and geometry of the synthetic peptide in contrast to the native state. We selected
3 mL injection volume, a 75 pg column and100 mM NH4HCO3 pH 7.8 as
operating conditions for purification of lunasin via preparative gel filtration
chromatography.
2.4.3 Application of adjusted enrichment and purification processes to
industrially produced tofu whey.
We used industrially produced whey to contrast our designed enrichment
process using ethanol and pH 4.5 (EtOHpH4.5) with the more commonly used
hot and cold drying alternatives to obtain solid fractions from liquid streams:
spray drying (SDW), and freeze-drying (FDW). The three samples were purified
via gel filtration chromatography as described in section 2.3.5. Chromatographic
profile (Figure 2.4A) clearly showed that the ethanolic-isoelectric concentration
process drastically switched the protein profile in the whey, making more
prevalent the peak associated with lunasin (retention time 88 min). Peaks for
lunasin (Figure 2.4B), compounds responsible for yellow coloration (Figure 2.4C),
and carbohydrates (Figure 2.4D) were present in the three samples at the same
retention times, suggesting that no evident conformational changes associated
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with size and geometry occurred to these set of compounds by exposure to the
drying temperature and conditions, or to the enrichment process. However, in
comparison to the whole whey, in our lunasin enriched material the concentration
of lunasin was considerably higher, while the presence of other compounds was
almost negligible. This demonstrates that ethanolic – isoelectric precipitation not
only removed an important quantity of undesired proteins, but other non- protein
compounds present in the whey. In addition, it favors the completion of the
chromatographic purification in a shorter time.
Electrophoretic and size exclusion chromatographic profile
(Supplementary Figure 2.2) of purified fractions collected at 78 and 88 min (F78
and F88 respectively), from the sample treated with our enrichment method,
showed that F78 still contained significant amount of the 14 kDa complex and
other proteins of similar size, while F88 mostly correspond to the 5 kDa lunasin.
Approximately 193 mg of F78 and 34 mg of F88 were obtained per liter of
industrial tofu whey, containing 46% and 80% w/w lunasin, respectively
(Supplementary Table 2.4). MALDI-TOF-MS analysis of the 5 kDa band in F78
and F88 (Table 2.3) indicated a 34% and 56% coverage of the 2S albumin
precursor, respectively, and 100% coverage of lunasin sequence, corroborating
the isolation of the peptide.
A six-step isolation process involving PBS extraction, ionic exchange
chromatography (IEC), treatment with a reducing agent, ultrafiltration, reverse
phase chromatography, and ultrafiltration, reported a yield of 442 mg lunasin/kg
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defatted soy flour with >99% purity [9]. This report based the estimation of purity
on the mere visualization of a unique electrophoretic band at 5 kDa in the final
product, leaving behind the presence other compounds, such as carbohydrates,
that are soluble in aqueous solutions and are present in the soybeans in
abundant quantities but cannot be visualized via SDS-PAGE. Another four-step
process that involved aqueous extraction, IEC, ultrafiltration, and gel filtration
chromatography, was able to obtain 1.3 g lunasin/kg defatted soy flour, with 80%
purity as assayed via HPLC [10]. Our three-step process (Figure 2.5) that
involved ethanolic precipitation, isoelectric precipitation, and gel filtration
chromatography yielded 772 mg/kg of dry tofu whey with at least 80% purity as
analyzed via HPLC, with the remaining fraction being proteins of slightly higher
molecular weight (Supplementary Figure 2.3 and Supplementary Table 2.4). This
process is simpler, faster and valorizes a by-product largely produced by the tofu
industry. Hence, our method can be used to obtain the naturally occurring
bioactive peptide lunasin in a more economical, and environmentally friendly
process leading to reduce wastage and increase utilization of tofu whey.
2.4.4 Biological activity of isolated lunasin
Oxidative stress and inflammation have been recognized as two of the
principal factors contributing to the onset and development of non-communicable
and infectious diseases [35]. The antioxidant and anti-inflammatory properties of
lunasin have attracted attention to this peptide as a promising alternative for the
prevention and treatment of some of these diseases [10,36,37]. Upon infection,
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components of pathogens, including the LPS outer membrane of gram-negative
bacteria, are recognized by innate immune cells such as macrophages, triggering
signaling cascades that lead to the expression and release of pro-inflammatory
cytokines and nitric oxide [38,39]. However, chronic inflammation derived from
the inappropriate regulation of this process can produce damage to the host cells
and lead to inflammation-related diseases [40].
To verify that the isolated lunasin maintained its biological activity, we
tested the ability of the two purified fractions, F78 and F88, obtained from
industrially produced whey treated with our designed enrichment method, to
reduce pro-inflammatory response in LPS-activated murine macrophages. No
detrimental effect over the viability of the immune cells (Figure 2.4E) was
detected upon treatment with increasing concentrations of the two fractions. No
effect was observed in most of the cases for fractions F78, while significant
reduction of the pro-inflammatory markers was observed for fraction F88 (Figures
2.4 F-H), corroborating that our isolated lunasin is biologically active, and that a
considerably high level of purity is required to exert the bioactive properties. The
30% reduction of TNF-α achieved by our isolated material at 2.4 mg/mL (190 µM
lunasin) is comparable to the 23% reduction of TNF-α reported using 200 µM of
synthetic lunasin under similar conditions of treatment of the same cell line [37].
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2.5 Conclusions
A simple and feasible approach combining ethanolic-isoelectric
precipitation and gel filtration chromatography was developed for the isolation of
bioactive lunasin from tofu whey. In contrast to current isolation methods that
waste valuable nutrients from the defatted soy flour or whole soybeans the
implementation of our approach would favor the generation of three valuable
products from the soybeans: tofu, an intermediate product resulting from the
ethanolic treatment of the whey with potential as a protein dietary supplement,
and a fraction highly enriched in lunasin. Our three-step process is competitive
with current alternatives in terms of the quantity and purity of the final product,
but faster and more sustainable. It promotes the valorization of a by-product
largely produced by the tofu industry and at the same time facilitates a better
utilization of soybean nutrients for the benefit and well-being of humans.
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Appendix
Tables and Figures
Table 2.1 Yield of products in tofu preparation at the laboratory scale.
Product
Dry Soybeans
Okara
Soy milk
Tofu
Whey

Units
g
g
mL
g
mL

Average
100 ± 0
289 ± 11
617 ± 29
197 ± 7
362 ± 20
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Figure 2.1 Ethanolic precipitation of high molecular weight proteins.
(A) SDS-PAGE, (B) molecular weight distribution profile, and (C) lunasin
immunoblotting of supernatants (A, B, and C) and precipitates (A and C) after
treatment of tofu whey with 20%, 30%, 40% or 50% v/v of ethanol (lines 1, 2, 3
and 4 respectively). Molecular weight marker (M), Non-treated tofu whey (W),
and lunasin standard (L) are included as references.
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Table 2.2 Characteristics of calcium and isoelectric precipitates from ethanolic
whey.
Parameter
pH 4.5
pH 5.5
Ca
ab
b
mg solid/mL whey
1.2 ± 0.1
1.0 ± 0.1
1.4 ± 0.1a
µg protein/mg solid
339 ± 90 ab
423 ± 55 a
247 ± 28 b
µg lunasin/mg solid*
59 ± 7a
70 ± 2a
39 ± 10b
% lunasin in solid
5.9 ± 0.7a
7.0 ± 0.2a
3.9 ± 1.0b
Daidzin (µg/mg)
3.7 ± 0.1a
3.8 ± 0.4a
2.9 ± 0.1b
Genistin (ng/mg)
294 ± 3a
295 ± 3a
215 ± 1b
Glycitin (µg/mg)
ND
ND
ND
Daidzein (µg/mg)
ND
ND
ND
Genistein (µg/mg)
ND
ND
ND
Glycitein (µg/mg)
ND
ND
ND
Trypsin Inhibitory Activity (TIA)
ND
ND
ND
ND: Non-detectable, *Estimated via ELISA. Different letters in the same
row indicate significant differences among treatments (p<0.05)
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Figure 2.2 Precipitation of soluble proteins from ethanolic whey.
After treatment of the whey with 30% ethanol, lunasin enriched fractions were
produced by precipitating remaining soluble proteins at pH 4.5 (line 1), pH 5.5
(line 2), or with calcium chloride (line 3). Protein precipitates were characterized
via (A) SDS-PAGE, (B) size exclusion chromatography, and (C) Western blot.
Lunasin (line L), Kunitz trypsin inhibitor (KTI), and Bowman-Birk inhibitor (BBI)
standards (line Std) were included for reference. (D) Cell viability and (E) release
of nitric oxide were measured as indicators of the biological activity of the lunasin
enriched fractions. LPS-activated murine macrophages were treated with
increasing concentrations of lunasin enriched fractions. Non-treated nonactivated cells (Control), and non-treated LPS-activated cells (LPS) were used as
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controls. Different letters indicate significant differences between the different
concentrations of the same sample (p<0.05).
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Figure 2.3 Adjustment of preparative gel filtration chromatography parameters.
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The effect of the mobile phase (Tris-HCl or ammonium bicarbonate), preparation
grade of the chromatographic column (30 or 75 pg) and sample volume injection
(0.5 or 3 mL) were evaluated. (A) Gel filtration chromatographic profile, (B-E)
lunasin, carbohydrates, and protein profiles under the different separation
conditions. Base conditions: 30 pg column, Tris- HCl mobile phase and 0.5 mL
injection volume (B), NH4HCO3 as mobile phase (C, D and E), 75 pg column (D
and E), 3 mL injection volume (E). Open arrows indicate lunasin peak. As
indicated in section 2.3.4, 3 mL of resuspended whey were purified using
NH4HCO3 mobile phase and 75 pg column. Consecutive fractions of eluent were
collected every 10 min. Fractions with a significant content of lunasin
corresponding to average retention times of 58, 68, 78, and 88 min (lines 1 to 4
respectively) were characterized via (F) SDS-PAGE, (G) western blot against
lunasin antibody and via (H) HPLC for molecular weight distribution profile.
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Figure 2.4 Isolation of lunasin from industrially produced tofu whey.
Industrially produced tofu whey was spray dried (SDW), freeze-dried (FDW), or
concentrated using 30% ethanol and pH 4.5 (EtOHpH4.5). Each sample was
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then purified via preparative gel filtration chromatography as described in section
2.3.5. Consecutive fractions of eluent were collected every 10 min and
characterized for (A) protein content, (B) lunasin content, (C) yellow color
intensity, and (D) total carbohydrates content. Fractions with a significant content
of lunasin, corresponding to average retention times of 78min (F78) and 88 min
(F88) were tested for bioactivity. (A) Viability, (B) production of nitric oxide, and
release of pro-inflammatory cytokines (C) IL-6, and (D) TNF-α were evaluated in
LPS-activated murine macrophages in the presence or absence of different
concentrations of fractions F78 and F88.

97

Figure 2.5 Process for the isolation of lunasin from tofu whey via ethanolicisoelectric precipitation and gel filtration chromatography.
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Table 2.3 MALDI-TOF-MS identification of the 5 kDa lunasin immunoreactive
bands in fractions obtained via gel filtration chromatography of ethanolicisoelectric enriched material from industrially produced tofu whey.
Protein identified
(NCBInr accession)

Fraction F88

2S albumin precursor

MOWSE
(20
ppm)

Sequence
coverage
(%)

462

34

Gm-c1019
Glycine max
(AW186094)

LLFCIAHTCS ASKWQHQQDS CRKQLQGVNL TPCEKHIMEK IQGRGDDDDD
DDDDNHILRT MRGKINYITR NEGKDEDEEE EGHMQKCCTE MSELRSPKCQ
CKALQKIMEN QSEELEEKQK KKMEKELINL ATMCRFGPMI QCDLSSDD_E
VKSNVVTCTY _HMM__FM

2S albumin precursor

841

56

Fraction F78

Gm-c1055
Glycine max
(BG042158)

GKMTKFTILL ISLLFCIAHT CSASKWQHQQ DSCRKQLQGV NLTPCEKHIM
EKIQGRGDDD DDDDDDNHIL RTMRGRINYI RRNEGKDEHE EEEGHMQKCC
TEMSELRSPK CQCKALHKIM ENQSEELEEK QKKKMENELI NLATMCRFGP
MIQCDLSSDD

Peptides matched
HIMEKIQGR
WQHQQDSCRK
KWQHQQDSCR
QLQGVNLTPCEK
SKWQHQQDSCR
FGPMIQCDLSSDD
KQLQGVNLTPCEK
IQGRGDDDDDDDDD
IQGRGDDDDDDDDDN
QLQGVNLTPCEKHIMEK
HIMEK
CCTEMSELR
ELINLATMCR
WQHQQDSCR
KWQHQQDSCR
WQHQQDSCRK
KWQHQQDSCR
QLQGVNLTPCEK
SKWQHQQDSCR
IMENQSEELEEK
FGPMIQCDLSSDD
KQLQGVNLTPCEK
IQGRGDDDDDDDDD
IMENQSEELEEKQ
IQGRGDDDDDDDDDN
IMENQSEELEEKQK

Matched peptides are shown in red, and the underlined segment corresponds to
lunasin peptide amino acid sequence (SKW…DDD).
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Supplementary material

Preliminary evaluation of okara and tofu whey as potential sources of lunasin
using direct calcium precipitation.
An alkaline proteinaceous extract from okara was prepared as follows: a
mixture of okara: water at a mass:volume ratio 1:10 was adjusted to pH 9.0 and
stirred at 80°C for 30 min to extract the soluble proteins present in the solid
waste. After cooling down to room temperature, the mixture was centrifuged at
9000 g for 30 min. Okara extract supernatant and whey were treated with 20mM
calcium chloride to induce direct precipitation of lunasin. Supernatant and
precipitate of each by-product after calcium treatment were evaluated for protein
and lunasin content as presented in Supplementary Table 2.1.
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Supplementary Table 2.1 Characteristics of calcium precipitates from okara and
tofu whey.

Parameter
mg of dry solid/g of
okara or mL whey
µg protein/mg dry solid
µg lunasin/mg dry solid
% Lunasin in solid

Okara
Supernatant Precipitate

Whey
Supernatant Precipitate

23 ± 4

11 ± 2

24 ± 1

0.21 ± 0.05

60 ± 4
0.74 ± 0.13
0.07 ± 0.01

5±1
0.43 ± 0.02
0.04 ± 0.00

91 ± 3
15 ± 1
1.46 ± 0.14

97 ± 14
38 ± 3
3.76 ± 0.41
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Supplementary Table 2.2 Reference standards for HPLC size exclusion
chromatography
Standard
Albumin
Aprotinin
Lunasin
Glucagon
Bradykinin Acetate
Bradykinin 1-5
Glutathione
Glycine

MW (Da)
66000
6500
5000
3842
1060
573
307
75

RT (min)
5.281
6.564
6.683
7.351
7.980
8.627
9.645
9.802
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Characterization of ethanolic precipitate form tofu whey
As part of the enrichment process, tofu whey is treated with 30% ethanol
to induce the precipitation of high molecular weight proteins. The ethanol
precipitate (EtOH-PPT) obtained during this step was characterized in contrast to
commercially available lunasin dietary supplements LunaRich Now (LNR),
LunaRich X (LRX), obtained from Reliv International, Inc. (Chesterfield, MO), and
to defatted soy flour (DSF) from MP Biomedicals (Ohio, USA). Cell viability and
release of nitric oxide were used as indicators of potential anti-inflammatory
activity of the products.
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Supplementary Table 2.3 Characterization of ethanolic precipitate form tofu
whey and commercially available lunasin containing products.
Parameter
µg protein/mg sample
µg lunasin/mg sample
µg lunasin/mg protein
% lunasin in solid

DSF
36 ± 1
3.4 ± 0.0
96 ± 2
0.3 ± 0.0

LRX
98 ± 3
5.6 ± 0.7
57 ± 6
0.6 ± 0.1

LRN
EtOH-PPT
41 ± 3
279 ± 33
3.4 ± 0.4 49.5 ± 5.3
83 ± 9
177 ± 4
0.3 ± 0.0 5.0 ± 0.5
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Supplementary Figure 2.1 Potential anti-inflammatory activity of ethanol
precipitate and commercially available lunasin containing products.
Cell viability (top) and release of nitric oxide (bottom) were measured in murine
macrophages activated with lipopolysaccharide, in the presence of different
concentrations of the ethanolic precipitate or commercial products. Non-treated
non-activated cells (-C), and non-treated LPS-activated cells (+C) were used as
controls.
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Characterization of fractions with relevant content of lunasin after enrichment and
purification of industrially produced tofu whey.
Industrially produced tofu whey was treated with 30% ethanol and then
adjusted to pH 4.5. The solid produced was resuspended and purified via gel
filtration chromatography. Fractions of the eluate were collected every ten
minutes and those with relevant content of lunasin were characterized.
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Supplementary Figure 2.2 Characterization of chromatographic fractions with a
significant content of lunasin.
(A) SDS-PAGE, (B) western blot against lunasin antibody and (C) molecular
weight distribution profile of fractions corresponding to retention times 48, 58, 68,
78, and 88 minutes (lines 1 to 5 respectively).
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Supplementary Table 2.4 Characteristics of purified fractions obtained from
industrial tofu whey via ethanolic-isoelectric precipitation and gel filtration
chromatography. F78 and F 88 correspond to eluates collected at 78- and 88-min
retention time.
Parameter
mg solid/L whey
µg protein/mg solid
µg lunasin/mg sample (HPLC)
% lunasin in solid

F78
F88
193 ± 33
34 ± 11
336 ± 32 227 ± 43
465 ± 3
804 ± 79
46.5 ± 0.3 80.4 ± 7.9
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Supplementary Figure 2.3 Corroboration of lunasin identity using antibodies
against different fractions of the peptide.
(A) SDS-PAGE, (B) Western blot using lunasin antibodies LUP 3 and (C) LUP 4
for fractions F88 (lane 1), F78 (lane 2) and synthetic lunasin peptide (lane 3).
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CHAPTER 3. LUNASIN MODULATES THE ACTIVATION OF
THE NLRP3 INFLAMMASOME AND REDUCES THE
SUSCEPTIBILITY TO INFLAMMATORY BOWEL DISEASE IN
IL-10-/- MICE
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3.1 Abstract
Inflammatory bowel disease (IBD) is a condition of chronic inflammation
that can cause severe damage to the gastrointestinal tract, compromising the
health and well-being of thousands of people worldwide. Our goal was to
investigate the protective effect of the soy peptide lunasin in an in vivo model of
susceptibility to IBD and to identify in vitro the potential mechanism of action. In
IL-10 deficient mice, oral administration of lunasin reduced the number and
frequency of mice exhibiting macroscopic signs of susceptibility to inflammation
and significantly decreased levels of the pro-inflammatory cytokines TNF-α, IL1β, IL-6, and IL-18 by up to 95%, 90%, 90%, and 47%, respectively, in different
sections of the small and large intestines. Dose-dependent decrease of caspase1, IL-1β, and IL-18 in LPS-primed and ATP-activated THP-1 human
macrophages demonstrated the ability of lunasin to modulate the NLRP3
inflammasome. The mechanism by which the inflammasome is modulated is
through reduced protein levels of NLRP3. For the first time, we demonstrated
that lunasin can decrease susceptibility to IBD in genetically susceptible mice by
exerting anti-inflammatory properties.

3.2 Introduction
Inflammatory bowel disease (IBD) is a gastrointestinal disorder
characterized by a state of chronic inflammation that results in severe damage of
the bowel [1]. This results in intolerable intestinal and extra-intestinal symptoms,
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and increases the risk of life-threatening conditions such as colorectal cancer
[1,2]. It is estimated that more than 6.8 million people worldwide suffer from
either Crohn’s disease (CD) or ulcerative colitis (UC), the two major forms of IBD
[3]. Immune cells and cytokines are crucial players in IBD, modulating the
initiation, development, recurrence, and exacerbation of the inflammatory
response and the associated clinical manifestations [4]. Hence, therapeutics
frequently used to treat IBD such as steroids, aminosalicylates, and
immunomodulators are molecules with strong immunosuppressive effects [5], or
biologics that blockade highly specific inflammatory key targets such as tumor
necrosis factor α (TNF-α), integrins, tyrosine kinases or their receptors [6].
However, serious adverse effects associated with these therapeutics include
opportunistic infections, peptic ulcers, hepatotoxicity, pancreatitis, renal
dysfunction, hypertension, myelosuppression, pulmonary fibrosis, and potential
correlation with some malignancies [7]. Therefore, it is essential to seek effective
and safe options to lessen intestinal inflammation with minimum or no adverse
consequences.
Genetic susceptibility that leads to a dysregulated immune response to
environmental triggers has been suggested as the potential underlying etiology of
IBD [8]. Although only 26% and 19% of inheritable CD and UC cases can be
explained by common genetic variants, progress has been made by identifying
163 susceptibility loci with direct implication in IBD, affecting pathways related to
lymphocyte activation, innate mucosal defense, and the production of pro112

inflammatory and anti-inflammatory cytokines, particularly IFN-γ, TNF-α, IL-12
and IL-10 [8]. IL-10 and IL-10 receptor defects result in a severe early onset of
the disease in humans, leading to intractable enterocolitis in infants and young
children [9]. IL-10 deficient mice (IL-10-/-) spontaneously develop colitis with
transmural inflammatory infiltrates, ulcers, epithelial hyperplasia, crypt
abscesses, and mucin depletion, which resemble histological characteristics of
the disease in humans [10].
Activation of the inflammasome nucleotide-binding oligomerization
domain-like receptor containing pyrin domain 3 (NLRP3) has been reported in
CD and UC patients with long-standing disease [11]. Also, the NLRP3
inflammasome has been found to play an important role in the development of
spontaneous colitis in IL-10-/- mice [12]. Inflammasomes are multiprotein
complexes that regulate the recruitment and activation of caspase-1, leading to
maturation of pro-IL-18 and pro-IL-1β into active forms which are subsequently
released to the extracellular environment, contributing to the inflammatory
response [13]. NLRP3 inflammasome activation is a two-step process. During the
priming stage, Toll-like receptors (TLR) agonists from pathogenic or commensal
bacteria, act as inflammatory stimuli by inducing NF-κB mediated expression of
NLRP3 and pro-IL-1β [14]. Then the activation stage is triggered by pathogen or
danger-associated molecular pattern molecules (PAMPs and DAMPs,
respectively) promoting the interaction and assembly of NLRP3 with the
apoptosis-associated speck-like protein (ASC) containing a caspase recruitment
113

domain (CARD) via the pyrin domain, facilitating the interaction between the ASC
and pro-caspase-1 CARD domains and mediating the cleavage of pro-caspase-1
into the active effector with proteolytic activity [14]. Blockade of the NLRP3
inflammasome by caspase-1 inhibitors has been shown to ameliorate
spontaneous colitis in IL-10-/- mice [12]. Specific events, such as ion potassium
efflux [15] and mitochondrial dysfunction, and particularly mROS [16], have been
implicated in the activation of the NLRP3 inflammasome. Mitochondrially targeted
antioxidants have been shown to suppress inflammasome-mediated cytokines
and improve the outcomes of induced colitis in vivo [17]. Consequently, targeting
the NRLP3 inflammasome has recently been proposed as a new therapeutic
strategy for the treatment of IBD [18].
Lunasin is a naturally occurring soybean peptide with antioxidant,
anticancer, and anti-inflammatory properties [19]. Lunasin decreases reactive
oxygen species and the production of the pro-inflammatory mediators including
TNF-α, IL-6, IL-1β, prostaglandin E2, and nitric oxide through inhibition of nuclear
factor – kappa-light-chain-enhancer of activated B cells (NF-κB) pathway [20].
The ability of lunasin to regulate different inflammatory processes significantly
involved in the burden of immune-related disorders has raised the scientific
interest in this peptide as a potential preventive and therapeutic strategy against
chronic diseases. Promising results have been found when evaluating lunasin in
in vivo models of breast, melanoma, lung, and metastatic colorectal cancer, as
well as cataracts, and cardiovascular disorders derived from lipid imbalance [20].
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However, the assessment of lunasin in the context of bowel inflammation
remains mostly unexplored. In this study, we aimed to explore the protective
effect of lunasin on in vivo susceptibility to spontaneous colitis and to investigate
in vitro the potential mechanisms involved in the modulation of the NLRP3
inflammasome.

3.3 Materials and Methods
3.3.1 Lunasin isolation
Lunasin enriched material was purified from tofu whey kindly provided by
Farm Foods LLC (Summertown, TN) as previously described [21]. Briefly,
ethanol was added to tofu whey to a final concentration of 30% v/v. After stirring
for 10 min and centrifugation at 15800 x g for 15 min, the supernatant was
transferred and adjusted to pH 4.5, followed by centrifugation under the same
conditions. The precipitate was freeze-dried. For further purification utilizing
preparative gel filtration chromatography (AKTA PURE protein purification
system, GE Healthcare Life Sciences, Piscataway, NJ), the freeze-dried powder
was resuspended in 100 mM ammonium bicarbonate pH 7.8 as mobile phase at
60 mg/mL, followed by filtration through a 0.45 µm nylon filter tip. Three mL of the
permeate was injected in the chromatograph and separated on a HiLoad 16/600
75pg Superdex column, at room temperature and 1mL/min mobile phase flow
rate. The fraction eluted between 83 and 93 min was collected, placed in a
shaking water bath at 40 °C for 5 min to remove the volatile salts from the mobile
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phase, and then freeze-dried. The final powder had a lunasin purity of at least
80% as assessed via HPLC.
3.3.2 In vivo experiments
Protocols for animal experiments were approved by the Institutional
Animal Care and Use Committee of the University of Tennessee Knoxville
(#2707-0619) and were conducted under the U.S. Public Health Service Policy
on Humane Care and Use of Laboratory Animals and following ARRIVE
guidelines. Eighteen IL-10-/- C57/BL6J 13-week-old male mice (Jackson
Laboratories, Bar Harbor, ME) were housed in pairs under standard controlled
conditions (12 h light/dark cycles, 30-50% relative humidity, 23 ± 3 °C) with free
access to water and chow diet provided ad libitum. After one week of
acclimatization, mice were randomly divided into three groups, control (n = 6),
lunasin (n = 6), and caspase inhibitor (CI, n = 6). For 35 consecutive days, oral
gavage of 100 µL of sterile water alone (control and CI groups) or containing 50
mg lunasin/kg body weight (bw) was performed. Based on the method described
by Nair and Jacob [22], the human equivalent dose of lunasin supplementation is
4 mg/kg bw. The CI group received daily intraperitoneal injection of caspaseinhibitor Ac-YVAD-cmK at 1.25 mg/kg bw for 24 days before euthanasia. Due to
the involvement of the inflammasome in the development of spontaneous colitis
in this animal model, the CI Ac-YVAD-cmK is often used as a control treatment
with positive outcomes [12]. On day 36, mice were euthanized via cervical
dislocation. The small intestine was harvested and divided into duodenum,
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jejunum, and ileum. Colon was dissected at the ileocecal junction and the length
was recorded. Every intestinal section was gently rinsed to remove luminal
contents and longitudinally dissected into two sections. One section of each
tissue was fixed in formalin and paraffin-embedded for histopathological
assessment, while the other half of each tissue was immediately frozen in liquid
nitrogen and stored at -80 °C for further analysis.
3.3.3 Macroscopic disease activity index (DAI)
Body weight and fresh stool were monitored daily and scored from 0 to 3
according to the following parameters: stool consistency (0: normal, 1: moist and
sticky, 2: soft, 3: diarrhea), hematochezia (0: normal color, 1: brown reddish
stool, 2: visible blood in stool, 3: rectal bleeding), and weight loss (0: <2%, 1: 2 to
5%, 2: 5 to 10%, 3: >10% compared to the bw at the beginning of the study). The
disease activity index was calculated as the sum of the scores for the three
parameters, with 0 being the minimum and 9 being the maximum.
3.3.4 Analysis of fecal occult blood
Samples of stool were collected from the cages every third day, freezedried, and ground to analyze the presence of occult blood by quantifying
hemoglobin content as previously reported [23].
3.3.5 Histopathological assessment
Hematoxylin and eosin-stained slides were used for histopathological
disease scoring in a blinded fashion by board certified veterinary pathologist
(MMS). Cellular infiltration, mucosal architecture, and epithelial changes were
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evaluated in the three sections of the small and large intestine. Crypt abscess
formation and depletion of goblet cells were also included for the evaluation of
the colonic tissue. Scores were assigned following the criteria described by
Erben et al for small intestine and colonic inflammation [24].
3.3.6 Quantification of pro-inflammatory cytokines and myeloperoxidase
activity (MPO)
Tissue extracts or cell culture supernatants were used for the
quantification of pro-inflammatory cytokines. Mouse TNF-α, IL-1β, and IL-6 were
from BioLegend (San Diego, CA), human IL-1β and mouse IL-18 were from
Invitrogen (Waltham, MA), human caspase-1 and IL-18 were from R&D Systems
(Minneapolis, MN). Immunoassays were performed as described by the protocol
provided by the manufacturer. Preparation of tissue extracts and evaluation of
MPO activity were performed following previously published methods [23].
3.3.7 Cell culture, differentiation, and assessment of viability
THP-1 monocytes (ATCC, Manassas, VA) were cultured in RPMI-1640
basal medium supplemented with 10% heat-inactivated fetal bovine serum and
1% penicillin/streptomycin at 37°C in a humidified 5% CO2 incubator. The same
incubation conditions were used for all the experiments. β-mercaptoethanol at
0.05 nM was added to the complete media for regular maintenance of the
culture. When required, cells were seeded at a density of 1 x 105 cells/well in 96well plates, or 1 x 106 cells/well in 6-well plates, incubated in complete media with
100 ng/mL of phorbol 12-myristate-13-acetate (Millipore Sigma, St. Louis, MO)
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for 48 h to induce differentiation into macrophages. A subsequent resting phase
of 48 h in complete media alone was allowed before the initiation of the indicated
experiment. After the specific treatment was performed, cell viability was
assessed by the MTS assay (Promega, Madison, WI) following the
manufacturer's protocol.
3.3.8 Activation of NLRP3 inflammasome via NLRP3 agonist
After the resting period, differentiated macrophages were primed for 6 h
with 1 µg/mL lipopolysaccharide (LPS) from Escherichia coli O55:B5 (Sigma, St.
Louis, MO) in plain media, in the presence or absence of lunasin at the indicated
concentration. Then, adenosine triphosphate (ATP) (Alfa Aesar, Tewksbury, MA)
was added to each well to reach a final concentration of 5 mM and incubated for
2 h. Treatment media was collected to test for pro-inflammatory cytokines and
cells were used for cell viability test or lysed and harvested for western blot
analysis. Plain media without LPS or ATP were used as the negative control.
3.3.9 Western Blot
Western blot was performed following standard protocol with the following
specifications: proteins in the gel were transferred to PVDF-membranes using a
Trans-Blot Turbo transfer system (Bio-Rad, Hercules, CA), membranes were
blocked with 5% non-fat dry milk in 0.01% Tween 20 Tris-buffered saline for 1 h
at room temperature, primary antibodies against the indicated antigens
(Proteintech, Chicago, IL) were incubated at 1:1000 dilution overnight at 4 °C,
and secondary antibody at 1:2000 dilution for 1 h at room temperature.
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Immunoreactive bands were visualized via chemiluminescence using a C-Digit
Blot scanner (LI-COR Biosciences, Lincoln, NE) and analyzed using Image
StudioTM software.
3.3.10 Mitochondrial reactive oxygen species (mROS)
Antimycin A is a powerful inhibitor of the mitochondrial respiratory chain
that blocks complex III and induces superoxide production [25]. THP-1
monocytes were incubated for 1 h with plain media with or without 5 mg/mL of
lunasin. Antimycin A from Streptomyces sp. (Sigma Aldrich, St. Louis, MO) was
added to a final concentration of 40 µg/mL and incubated for 5 h. After removal of
the treatment media, cells were incubated for 30 min with 3 µM MitoSOx TM
(Thermo Scientific, Waltham, MA), washed with Hank's balanced salt solution
(HBSS), and then analyzed using a MACSQuant10 flow cytometer (Miltenyi
Biotec, Auburn, CA). For fluorescence microscopy, 1 x 105 cells/well were
seeded in 8-well ibidi µ-slides and differentiated into macrophages as indicated in
section 3.3.7. After the resting phase, cells were treated with lunasin and
antimycin A as previously described. The treatment media was collected to
evaluate pro-inflammatory cytokines, and the cells were incubated with MitoSOx
probe. Micrographs of the cells were captured using bright-field and red
fluorescence channels in an EVOSTM M7000 microscope (Invitrogen, Waltham,
MA) using a 20x objective. The number of positively stained cells was manually
counted in the merged image of at least six different fields taken for each
replication.
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3.3.11 Activation of the inflammasome via induced K+ efflux
Differentiated macrophages were primed for 6 h with or without LPS, in
the presence or absence of 5 mg/mL lunasin. K+ conditioned media consisted of
K+ free PBS supplemented with KCl to reach the specified concentration of
potassium (0, 0.5, 1.0 or 5.0 mM). Priming media was removed and K +
conditioned media with or without 5 mg/mL of lunasin was added to the cells and
incubated for the specified time to induce inflammasome activation. After
treatment, K+ conditioned media was collected and used for the quantification of
pro-inflammatory cytokines. Regular growth media was used as control to
compare the effect of K+ conditioned media.
3.3.12 Statistical analysis
A Principal Component Analysis (PCA) of the data from in vivo
experiments was performed using MATLAB (The Mathworks Inc., USA). An 18 x
127 matrix was created containing the following data: daily relative bw, stool
consistency and hematochezia scores, colon length, myeloperoxidase activity,
and pro-inflammatory cytokines for the duodenum, jejunum, ileum, and colon, for
every mouse belonging to the three treatment groups. The technique of Wilks'
lambda was carried out to select the variables with higher discriminant potential
among treatments. A 18 x 42 matrix was created with the 33% of variables with
the highest lambda coefficient and used to generate the PCA model with the
graphical user interface for PCA developed by the Milano Chemometrics and
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QSAR Research Group, Department of Earth and Environmental Sciences,
University of Milano–Bicocca, Milano, Italy [26].
Results are reported as mean ± SEM for in vivo experiments, and as
mean ± SD for in vitro analyses. Significant differences (p < 0.05) were assessed
using the non-parametric Mann-Whitney test, or the parametric t-student test,
accordingly, when comparing two treatments. ANOVA followed by the post hoc
Tukey test, was used for the comparison of three or more treatment groups.

3.4 Results
3.4.1 Oral administration of lunasin attenuated macroscopic indicators of
intestinal inflammation and reduced pro-inflammatory cytokines in the
bowel of IL-10-/- mice.
Body weight loss, diarrhea, and the presence of blood in the stool are
among the most common manifestations of IBD [1]. We applied a scoring system
to keep track of noticeable changes related to these symptoms. No significant
decrease in the average bw was observed for any group at any time during the
experiments (Figure 3.1A). However, our records indicated that decreases of up
to 7, 6, and 8% of the initial bw occurred in individual mice for the
control, lunasin, and CI groups, respectively, at different time points. Also,
although no significant differences were found between control
and lunasin groups on any given day, the trend indicated that
while lunasin administration maintained constant bw, control mice gradually
gained weight over time. Interestingly, administration of the CI resulted in a
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significantly lower relative bw in comparison to lunasin supplementation between
days 12 and 16, and significantly lower relative bw than the control over the
last 12 days of the experiment.
Upon visual inspection, no evident blood was identified in the stool or
perianal region of any mice, but variation in the color of the fecal matter towards
a red tone, receiving a score of one, was registered more frequently for the
control group than for the lunasin and CI groups (Figure 3.1B). To account for the
possible presence of occult blood in the fecal matter, hemoglobin content was
measured in the stool sample. Figure 3.1C revealed two periods of time when the
presence of hemoglobin, for the control group, was up to six times higher than
the baseline. These results suggest that potential minor intestinal injuries led to a
subtle but recurrent presence of blood in the stool of control mice, which could
not be detected by simple inspection, but enough to produce a change in the
color of the feces. Moreover, we found that with the lack of treatment, stool
became stickier and softer (scores 1 and 2, respectively) between two and three
times more often for the control group than for treated mice (Figure 3.1D). The
disease activity index (Figure 3.1E) indicated that, overall, the
animals exhibited mild macroscopic symptoms of bowel inflammation, with
scores 1 and 2 being the more frequent for all the groups. The maximum scores
observed for individual mice were 4 (1 mouse each in control and lunasin groups)
and 3 (4 mice in control, 1 in lunasin, and 2 in CI groups). DAI scoring
was strongly affected by the observed decrease in bw in the CI group. Taken
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together, our observations indicate that the susceptibility to minor inflammatory
events (frequency and severity) was reduced when oral supplementation of
lunasin was provided.
To further evaluate the effect of lunasin administration on the intestinal
tissues, we harvested the small and large intestines at the end of the experiment.
We observed that the characteristic colon shortening in IL-10-/- mice (Figures
3.1F and 3.1G) was significantly alleviated by lunasin, exhibiting colons on
average 13 mm longer than those from the control and CI groups. Colon
shortening or stiffening is a potential outcome of the involvement of the mucosal
and submucosal layers of the colon during chronic inflammation [27], hence we
examined for potential microscopic morphological alterations. Interestingly,
histomorphology evaluation indicated that neither the colon nor the small
intestine had significant structural changes associated with inflammation. No
damage in mucosal architecture, epithelial changes, depletion of goblet cells, or
formation of crypt abscess was detected in any intestinal section. Low cellular
infiltration with scattered individual eosinophils was seldomly observed in
different sections of the small intestine in random mice but was common in the
colonic mucosa of most mice in all the groups. Histological
evaluation agreed with the macroscopic observations as the possible
inflammation flares that led to the presence of blood in the stool occurred during
the first two weeks of the experiment, but no indicators of inflammatory events
were observed during the last weeks.
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The potential contribution of immune cells to intestinal inflammation was
investigated by quantifying MPO activity and levels of pro-inflammatory cytokines
in the tissues. MPO is an enzyme that catalyzes the production of potent reactive
oxygen species and has been directly correlated with immune cell trafficking
during intestinal inflammation [28]. No significant differences were detected
in MPO activity among the three groups for any of the intestinal
sections. Neutrophils are a major source of MPO [29], hence these results
corroborate histological findings and indicate that, at least by the end of the
experiment, the presence and activity of granulocytes (neutrophils and
eosinophils) in the intestine were not significant.
The profile of pro-inflammatory cytokines for the four intestinal sections of
each mouse is outlined in Figure 3.2A. Although some sections exhibit higher
levels of cytokines than others, not all the mice in the same treatment group are
identically affected. The dissimilar distribution of the proinflammatory
cytokines throughout the bowel for mice sharing the same environmental
conditions, genetic background and feeding patterns, serves as a display of the
inherent variability in predisposition to inflammation that characterizes IBD. We
observed that, on average, TNF-α (Figure 3.2B) and IL-1β (Figure 3.2D) were
prevalent in the distal regions of the bowel (ileum and colon), while IL-6 (Figure
3.2C) was more evenly distributed among all the sections and IL-18 (Figure 3.2E)
was more strongly present in the proximal regions of the intestine (duodenum
and jejunum). Reports show increased levels of TNF- α, IL-6, and IL-18, relative
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to healthy controls, in biopsies of CD and UC patients in absence of mucosal
markers of damage, indicating that these cytokines may exert immune activating
roles without triggering immediate tissue injury [28]. Lunasin effectively reduced
IL-18 in the colon by 47%, IL-6 in the jejunum by 90%, IL-1β in the duodenum
and colon by 90% and 80%, respectively, and TNF-α in the colon by 95%. In
contrast, the administration of caspase-1 inhibitor led to a reduction of IL-1β that
was only significant in the colon but like those observed for lunasin treatment in
the small intestine. Caspase inhibition led to a significant decrease of TNF-α as
well, but not IL-18, in the ileum and colon.
3.4.2 Principal component analysis of characteristic in vivo parameters
Considering the high variability observed, we performed a multivariate
analysis via PCA to establish the potential categorization of the mice based on
the evaluated variables. We observed that the three treatment groups can
be clearly differentiated (Figure 3.3A). The control group was characterized by a
markedly elevated level of the pro-inflammatory cytokines TNF-α and IL-1β in the
duodenum, ileum, and colon, and IL-6 in the jejunum, a noticeably softer
stool consistency on days 15, 19, 27, and 30, and a perceptible change in the
color of the stool on days 9, 12, and 22 that was probably due to the presence of
occult blood (Figure 3.3B). The distribution of the relative bw indicate
that the lunasin group had a heavier bw during the first 10 days of the
experiment, while the control group weighed heavier for the last 10 days, and
the CI-treated group had the lowest bw throughout the study. Collectively,
126

evaluation of macroscopic manifestations and intestinal tissues suggests that
potential inflammatory events occurred in the intestines of mice in the control
group. Administration of lunasin was effective in alleviating these events and
reduced pro-inflammatory cytokines throughout the bowel.
3.4.3 Lunasin modulates the activation of the NLRP3 inflammasome.
To address the potential role of lunasin in the modulation of the
inflammasome, we used LPS-primed and ATP- activated differentiated THP-1
human macrophages with or without lunasin treatment. No detrimental effect was
observed over the viability of the cells upon exposure to the different stimuli
(Figure 3.4A). Priming with LPS induced a significant increase in
the extracellular concentration of IL-1β (Figure 3.4B) and IL-18 (Figure
3.4C). The presence of both cytokines in the medium was further increased by
the addition of ATP. We observed a dose-dependent decrease in the production
of these cytokines in the presence of lunasin. At 2.5 mg/mL lunasin, the release
of IL-18 and IL-1β was significantly reduced by 40% and 45%, respectively. At a
concentration of 5.0 mg/mL, their extracellular concentration was reduced by
63% (IL-18) and 67% (IL-1β). This dose-dependent reduction observed upon
lunasin treatment suggests the involvement of a common upstream mechanism.
The shared activator molecule caspase-1 (Figure 3.4D) had the same level of
reduction in concentration (42% and 66% for 2.5 and 5 mg/mL treatments,
respectively). To further clarify the potential role of lunasin, we analyzed
the protein levels of the molecules involved in the assembly of the NLRP3
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inflammasome (Figure 3.4E). Lunasin treatment led to a significant 3-fold
decrease in the sensing molecule NLRP3, with no significant effect on ASC and
pro-caspase-1. These data indicate that the modulatory effect of lunasin over
the pro-inflammatory cytokines IL-18 and IL-1β was mediated by the abrogation
of NLRP3.
3.4.4 Lunasin-induced decline of extracellular IL-1β is independent of
mROS.
To assess whether the antioxidant properties of lunasin can be translated
into the mitochondria, we used antimycin A to induce mROS production.
Challenging the cells with antimycin A led to a 6-fold increase of IL-1β (Figure
3.5A) that was reduced by half in the presence of lunasin. Detection and
quantification of mROS by the mitochondria-targeted probe MitoSOxTM, via
fluorescence microscopy (Figures 3.5B and 3.5C) and flow cytometry (Figures
3.5D and 3.5E) revealed that non-stimulated cells exhibit basal levels of mROS.
The number of cells and the intensity of the staining, which accounts for mROS
present in the cells, were significantly increased by antimycin A. No effect was
observed in the presence of lunasin, demonstrating that the decreased release of
IL-1β to the extracellular media was mediated by mechanism independent of
mROS.
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3.4.5 Lunasin-induced decline of extracellular IL-1β is not mediated by
blockade of potassium efflux.
Efflux of intracellular K+ has been demonstrated as the common and vital
upstream trigger required to induce the assembly of the inflammasome [15].
Therefore, to investigate the potential involvement of lunasin in this process, we
manipulated the extracellular concentration of K+ to induce a natural efflux of the
ion and the consequent activation of the NLRP3 inflammasome in the presence
and absence of lunasin. First, we exposed LPS-primed cells to media with
reduced K+ levels for different time-lengths and quantified the release of IL-1β
(Figure 3.6A). At 15 and 60 min of treatment, no significant differences on IL-1β
were observed among the reduced concentrations of extracellular K +. After 2 h of
exposure to reduced K+, the concentration of the pro-inflammatory cytokine in the
extracellular environment was inversely proportional to the concentration of
extracellular K+ and was significantly different among all the tested conditions.
This indicates that approximately 2 h is needed for the cells to elicit a response
proportional to the extracellular levels of K+. During this time, the cells sense and
then react to the decreased levels of K+, activate the inflammasome, and release
mature IL-1β. Hence, 2 h was selected as treatment time for further analysis.
Next, we compared the viability and the release of IL-1β and IL-18, in nonprimed (LPS -) and LPS-primed (LPS+) cells exposed to different concentrations
of extracellular K+. K+ free medium had a detrimental effect by decreasing viable
cells between 20 and 40%, while 0.5 mM only decreased viability of non-primed
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cells by 8% (Figure 3.6B) when compared to cells maintained in regular media.
At 1.0 and 5.0 mM, the observed significant increase in viability is probably due
to an incremented metabolic activity of the cells associated with K+ efflux. K+
concentration lower than 1.0 mM was enough to induce activation of the
inflammasome in primed and non-primed cells, leading to a significantly
increased release of IL-1β (Figure 3.6C) and to a lower extent of IL-18 (Figure
6D). These results are consistent with previous observation reported by MuñozPlanillo et. al in bone marrow derived macrophages [15], indicating that a low
concentration of K+ in the extracellular media is enough to activate the NLRP3
inflammasome, in absence of a priming signal or an NLRP3 agonist. In our study,
the high levels of IL-1β and IL-18 concomitant to the reduced viability in K+ free
media suggests that this condition may be detrimental to the cells. Pyroptosis is a
form of cell death regulated by the activation of caspases via the inflammasome
[30]. Though pyroptosis may be occurring in all the tested concentrations, it
seems to start becoming significant at [K+] of 0.5 mM or lower. Based on these
observations, we selected 1.0 mM K+ as the appropriate condition to test the
involvement of lunasin in the modulation of the inflammasome triggered by
potassium efflux.
First, we evaluated the effect of lunasin treatment during the priming
phase. We primed the differentiated macrophage with LPS (LPS+) in the
presence or absence of lunasin (Lunasin+ or Lunasin- respectively). Cells treated
with lunasin only (LPS- and Lunasin+) and non-stimulated cells (LPS- and
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Lunasin-) were used as controls. At the end of the priming phase, the media was
replaced by 1.0 mM K+ conditioned media for 2 h to induce the activation of the
inflammasome. Release of IL-1β (Figure 3.6E) and IL-18 (Figure 3.6F) was
evaluated after the priming and activation phases. During the priming phase we
did not detect the release of IL-1β by non-stimulated cells, but a significant
release was observed in cells treated with lunasin alone. LPS-priming alone
induced the release of IL-1β, but it was reduced by 60% when primed cells were
simultaneously treated with lunasin during the priming phase. After activation,
extracellular IL-1β increased for all samples as expected. However, LPS-primed
only, lunasin-treated only, and cells primed in the presence of lunasin, all
exhibited the same concentration of IL-1β after activation. In contrast, IL-18 was
detected during the priming phase in all the samples, although the concentration
in non-stimulated cells was significantly lower. The release of IL-18 was boosted
after inflammasome activation, but surprisingly the highest levels were observed
when cells had been treated with lunasin. It is possible that the presence of
lunasin somehow leads to the accumulation of intracellular pro-IL-18, that upon
induction of K+ efflux was activated and released to the extracellular
environment. By contrasting these results with those observed in Figures 3.4B
and 3.4C we inferred that the activity of lunasin may not be limited to the priming
step.
Then, in a different approach, we examined if lunasin could be engaged in
the modulation of K+ efflux during the activation phase, by evaluating the cellular
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response in the presence or absence of the peptide. We postulated that if lunasin
was able to inhibit K+ efflux to some extent, extracellular concentration of both
cytokines (in both LPS-primed and non-primed cells) should be lower than in
conditions where lunasin was absent. This was only observed for IL-1β produced
by LPS-primed cells (Figure 3.6G). As no positive effect was observed in the
extracellular concentration of IL-18 (Figure 3.6H) under any condition, we
deduced that lunasin was not able to inhibit potassium efflux.

3.5 Discussion
Here, for the first time, we have demonstrated that lunasin decreases
markers associated with susceptibility to chronic intestinal inflammation in vivo.
We further demonstrated the direct inhibitory role of lunasin in the maturation of
the pro-inflammatory cytokines IL-18 and IL-1β by impacting the activation of the
NLRP3 inflammasome via reducing the protein levels of the sensing molecule
NLRP3. IL-10 acts as an anti-inflammatory cytokine that moderates the
inflammatory response triggered by bacterial antigens [31]. It can suppress the
release of pro-inflammatory cytokines and regulate the differentiation,
proliferation, and effector functions of different subsets of innate and adaptive
immune cells, acting as a key mediator of immunotolerance [31,32]. Upon the
defective or absent immunoregulatory function of IL-10, intestinal homeostasis is
lost, leading to a dysregulated inflammatory response characterized by the
persistent activation of pro-inflammatory pathways that result in adverse
consequences for the intestinal tissue [10].
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Our results indicate that the exacerbated levels of pro-inflammatory
signals occurring in the bowel, and the frequency of spontaneous intestinal
symptoms, due to the absence of IL-10, can be modulated by the oral
administration of lunasin. Upon the absence of IL-10, antigens from the natural
intestinal microflora trigger an abnormal release of pro-inflammatory signals that
are harmful to the intestine and lead to disease symptoms (loss of bw, diarrhea,
and intestinal bleeding). When lunasin was administered, the mechanisms
involved in the production of those pro-inflammatory signals, particularly TNF-α,
IL-6, IL-18, and IL-1β, are hindered, counteracting the inflammatory imbalance,
and therefore reducing the adverse consequences. These observed effects
indicate the immunomodulatory potential of lunasin peptide as a strategy to
return the balance lost when natural immunomodulatory mechanisms fail. The
negative impact of the caspase inhibitor over bw can be explained by the role of
caspase-1 in the regulation of metabolic functions that influence body weight,
such as glucose homeostasis and lipid metabolism [33]. Treatment of obese
mice for two weeks with caspase-1 inhibitors has shown a decreased gain of
body weight accompanied by an altered composition of the white adipose tissue
[34].
Our research group reported that pepsin and pancreatin hydrolysis can
impair the ability of lunasin preparations to inhibit activation of the inflammasome
[35]; however, differences in the in vitro and in vivo digestion mechanisms could
result in different digestion products with distinct biological activity. In addition, it
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is important to note that the lunasin enriched preparation contained considerable
amounts of other proteins that were affected by the proteolytic process. It is
possible that the decrease observed in the inflammasome inhibitory activity was
the result of the diminished contribution of these components, rather than a direct
result of lunasin digestion. This idea is supported by a recent report that indicates
the antihypertensive and antioxidant activity of fragments released from the in
vitro gastrointestinal digestion of synthetic lunasin, as well as their protective
effect against oxidative damage and inflammatory stimulation of murine
macrophages [36]. Our findings corroborate that upon oral administration, lunasin
digestion products exert anti-inflammatory properties and can efficiently decrease
levels of pro-inflammatory cytokines along the small and large intestines.
Biodistribution of lunasin derived peptides along the bowel may be responsible
for the variable activity observed in the cytokine’s profile for each intestinal
section. The substantial impact observed in the levels of IL-1β and IL-18
in lunasin treated mice suggests that the peptide could have a modulatory role
over the inflammasome.
Liu et al. reported that the activity of NLRP3 inflammasome was elevated
before colitis onset, progressively increasing as the disease worsened, and
reached a maximum peak when the macroscopic indicators appeared [37].
Hence, this inflammatory mechanism has been proposed as a new therapeutic
target in the pursuit of better clinical outcomes for IBD [18,38]. Here we
demonstrated that lunasin can modulate the activation of the NLRP3
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inflammasome. The observed trends during inflammasome activation triggered
by potassium efflux indicate that the presence of the peptide during the activation
phase is necessary for limiting the release of the mature IL-1β but not of IL-18. In
addition, under the absence of pathogenic stimuli, lunasin can act as a priming
signal to induce inflammasome activation at a lower extent and appears to
promote the accumulation of pro-IL-18, but these effects are altered by the
presence of inflammatory signals. These observations are in agreement with
recent studies that have demonstrated immunomodulatory activity of lunasin by
the upregulation of pro-inflammatory signals such as IL-6 and IL-1β in dendritic
cells [39], TNF-α, IL-1β, and COX-2/ PGE2 in ex-vivo explants of human mucosa
[40], and interferon-γ and granzyme B in natural killer cells [41]. Our results are
the first report demonstrating the upregulation of IL-18 and IL-1β in human
macrophages. Further investigation is required to corroborate our observations
and identify the potential mechanisms that regulate the observed effect over IL18.
The mechanism of action of lunasin does not involve mitochondrial ROS
or a direct inhibitory effect over potassium efflux, but rather the blockade of the
NLRP3 inflammasome by reducing the protein levels of NLRP3. NLRP3
transcriptional regulation is dependent on the NF-κB pathway [18]. NF-κB, one of
the most important regulators of proinflammatory gene expression, controls the
synthesis of TNF-α, IL-6, IL-1β, and IL-8, and the expression of COX-2, among
others, upon activation by pro-inflammatory signals such as PAMPs and pro135

inflammatory cytokines [42]. Treatment of RAW 264.7 LPS-activated
macrophages with lunasin reduced the activation of NF-κB by inhibiting the
translocation of p50 and p65 subunits of NF- κB to the nucleus, impacting its
transcriptional activity [43]. Therefore, it is highly probable that inhibition of the
NF-kB transcriptional activity is responsible not only for the observed decreased
protein levels of NLRP3 in vitro but the reduced levels of TNF-α and IL-6 in vivo.
Our observations suggest that the effect of lunasin is not limited to the
downregulation of NLRP3 during the priming phase but is rather more important
during the activation phase. Upon activation, the release of mature IL-1β serves
as a sustained and rising priming signal that continuously triggers the NF-kB
pathway, leading to the transcription of NLRP3 and pro-IL-1β, which are then
activated and contribute to the progressive amplification of inflammation. The
inhibitory activity of lunasin over NLRP3 appears to significantly diminish this
feedback amplifying loop. It is essential to note that in contrast to NLRP3 and
pro-IL-1β that are transcriptionally regulated by NF-κB, pro-IL-18 is constitutively
expressed in nearly all cells in humans and animals, including endothelial cells,
keratinocytes, and intestinal epithelial cells, but the active form is mostly released
from macrophage and dendritic cells [44].
The NLRP3 inflammasome responds to a wide variety of intracellular
stimuli such as pore-forming toxins from gram-positive and gram-negative
bacteria, RNA and DNA viruses, and yeasts, indicators of damage such as ATP,
monosodium urate crystals, amyloid-β aggregates, and particulate matter such
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as silica, alum, and asbestos [30]. Also It has been reported that “non-canonical”
activation of the NLRP3 inflammasome is mediated by the direct sensing of
cytosolic LPS by caspase-11 in mice, and its human orthologs caspases 4/5 [30],
which explains the increased levels of IL-1β and IL-18 observed during the
priming phase without further activation stimuli. Aberrant expression and
activation of the NLRP3 inflammasome due to polymorphism, gain of function
mutation, and constant exposure to agonist stimuli have been implicated in the
pathogenesis of multiple chronic degenerative diseases, including IBD,
Alzheimer, atherosclerosis, osteoarthritis, as well as other autoimmune disorders
such as lupus erythematosus and corneal inflammation-related diseases [18,45].
Therefore, the inhibitory activity of lunasin over the NLRP3 inflammasome is not
only relevant in the context of IBD but can be highly beneficial in the
management of other immune-related diseases. Our results not only
demonstrate the modulatory properties of lunasin over the NLRP3 inflammasome
but for the first time prove positive outcomes in an in vivo model of IBD. This
indicates that lunasin supplementation is a promising strategy to control early
manifestations and the potential onset of IBD.
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Appendix

Figure 3.1 Lunasin attenuates macroscopic markers of disease.
(A) Variation of relative body weight, (B) frequency of hematochezia score, (C)
average content of hemoglobin in stool as indicator of occult blood, (D) stool
consistency score heatmap, (E) disease activity index (DAI) heatmap, and (F and
G) colon length. Results are presented as mean ± SEM. CI: group administered
with caspase inhibitor. * indicates statistically significant differences in relative
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body weight between the CI and lunasin groups from day 12 to 16, and between
the CI and control groups over the last 12 days of the experiment, or in colon
length between the control and lunasin groups.
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Figure 3.2 Lunasin decreases intestinal levels of proinflammatory cytokines.
(A) Heatmaps and (B-E) bar graphs of TNF-α, IL-6, IL-1β, and IL-18 in the
indicated sections of the small or large intestine. In the heatmaps, D, J, I, and C
indicate duodenum, jejunum, ileum, and colon, respectively. Results are
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presented as mean ± SEM. Different letters indicate significant differences
between the treatment groups within the same intestinal section (p< 0.05).
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Figure 3.3 Principal component analysis showing the overall effect of lunasin
over the characteristic IBD parameters evaluated in vivo.
(A) Score plot and (B) loading plot for the first two principal components (PC1
and PC2) that explain 63% of the variance of the 42 variables with higher
discriminatory potential preselected using the method of Wilk’s lambda. The
matrix was generated using the following data: relative body weight (W), stool
consistency scores (SC), and hematochezia scores (VB) from day 1 to 35, colon
length (CL), MPO activity (M), IL-18 (18), IL-1β (1B), TNF-α (T), IL-6 (6) for the
duodenum (D), jejunum (J), ileum (I), and colon (C).
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Figure 3.4 Lunasin abrogates the activation of NLRP3 inflammasome.
(A) Cell viability, (B) IL-1β, (C) IL-18, and (D) caspase-1 concentration in the
extracellular media, (E) cellular protein levels of inflammasome components, and
(F) quantification of the protein levels of NLRP3, upon LPS-priming and ATPactivation of the NLRP3 inflammasome in differentiated THP-1 human
macrophages in the presence or absence of lunasin. Results are presented as
mean ± SD. Different letters indicate significant differences between the
treatments (p< 0.05).
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Figure 3.5 Modulation of the NLRP3 inflammasome by lunasin is independent of
mitochondrial ROS.
Production of (A) IL-1β and mitochondrial ROS as detected and quantified by
fluorescence microscopy (B and C) or flow cytometry (D and E) upon challenge
with antimycin A in the presence or absence of lunasin. Results are presented as
mean ± SD. Different letters indicate significant differences between the
treatments (p< 0.05).
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Figure 3.6 Lunasin reduces extracellular IL-1β during the activation phase but
does not affect potassium efflux.
Extracellular concentration of IL-1β (A, C, E and G) or IL-18 (D, F and H), and
cell viability (B) evaluated in differentiated THP-1 human macrophages exposed
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to different priming and activation conditions. (A) Activation of LPS- primed cells
for different times with K+ conditioned media. (B, C and D) LPS-primed (LPS+)
and non-primed (LPS-) cells were activated for 2 h with K+ conditioned media. (E
and F) Cells primed with (+) or without (-) LPS and/or lunasin, and then activated
for 2 h with 1.0 mM K+ conditioned media. (G and H) Cells primed (LPS+) or not
(LPS-) with LPS, and then activated with 1.0 mM K+ conditioned media with or
without lunasin. Results are presented as mean ± SD. Different letters and *
indicate significant differences between the treatments (p< 0.05).
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CHAPTER 4. CHEMOPREVENTIVE EFFECT OF LUNASIN IN
AOM/DSS-INDUCED COLITIS-ASSOCIATED COLORECTAL
CANCER IN MICE
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4.1 Abstract
Colitis-associated colorectal cancer (CA-CRC) accounts for the second
cause of death among patients with inflammatory bowel disease (IBD). The soyderived bioactive peptide lunasin has demonstrated in vitro anti-inflammatory and
anti-cancer properties, as well as chemopreventive properties in vivo. However,
the potential effect of lunasin in CA-CRC has not been addressed. In this study,
we used an in vivo model of CA-CRC induced by azoxymethane and dextran
sulfate sodium to evaluate the effect of oral administration of lunasin over the
macroscopic symptoms of the disease, markers of inflammation, and tumor
burden. Lunasin administration lessened the manifestation of the disease by
facilitating the gain of body weight and accelerating the recovery of stool
consistency during periods of mild and moderate inflammation. This effect was
accompanied by a reduction in neutrophils infiltration (p=0.024) and activity
(p=0.062), attenuated damage of the mucosal architecture (p=0.68), and the
increased levels of the marker of epithelial integrity E-cadherin (p=0.049).
Prevention of spleen enlargement (p=0.039) and lowering concentration of the
pro-inflammatory cytokine TNF-α in the serum (p=0.029) suggested a potential
systemic effect of lunasin. Treatment with lunasin reduced tumor incidence and
tumor multiplicity (p=0.036) and mitigated the malignant transformation of
dysplastic lesions. Our findings demonstrated for the first time the antiinflammatory and chemopreventive properties of lunasin in CA-CRC and suggest
the peptide as a promising protective agent against IBD-associated cancers.
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4.2 Introduction
Colorectal cancer (CRC) is the second most deadly cancer in the United
States, and the incidence of the disease is rapidly shifting toward younger
populations [1]. Although the most prevalent forms of CRC are sporadic and
familial-related, a higher risk of developing colitis-associated colorectal cancer
(CA-CRC) is prevalent in patients affected by inflammatory bowel disease (IBD)
[2]. IBD, which comprises ulcerative colitis (UC) and Crohn’s Disease (CD), is a
condition of persistent inflammation in the gastrointestinal (GI) tract that can
cause severe damage in the small and large intestines [3]. CA-CRC is one of the
most serious and life-threatening consequences of UC [4]. The risk of developing
CA-CRC is estimated at 2% by 10 years, 8% by 20 years, and 18% by 30 years
after UC diagnosis [5]. CA-CRC is the second most common cause of mortality
among IBD patients after cardiovascular diseases, accounting for 10 to 15% of
deaths [5,6]. Regular surveillance colonoscopy, polypectomy, and
proctocolectomy to remove affected areas, are the standard mechanism for early
detection and prevention of CA-CRC [4].
The association between chronic inflammation and cancer has been
widely reported. Prolonged and extended colitis, family history of CRC, early
onset of the IBD, severity of inflammation, and chronic inflammation in the bile
ducts highly contribute to the increasing risk of CA-CRC [7]. Pro-inflammatory
cytokines produced by the activated immune cells present in the affected tissue
have been shown to contribute to tumor growth [8]. Inflammatory pathways,
157

particularly the nuclear factor – kappa-light-chain-enhancer of activated B cells
(NF-κB) pathway, have been recognized as key linkers between inflammation
and cancer [9]. These pathways are involved in tumor initiation, promotion, and
progression by upregulating the expression of anti-apoptotic genes and
stimulating cell proliferation and angiogenesis via pro-inflammatory mediators
[10]. TNF-α, one of the main pro-inflammatory downstream products of the NFκB pathway, not only plays a key role in IBD [11], but also has been associated
with tumor initiation via the induction of reactive oxygen species, promoting DNA
damage, stimulating the expression of pro-angiogenic chemokines, and further
activating the NF-κB pathway [10]. Hence, the use of anti-inflammatory
therapeutics in IBD patients is also considered a chemopreventive strategy [4].
The consumption of plant-derived diets has been largely associated with
health benefits. Numerous studies have demonstrated the beneficial effect of soy
and soy products against cardiovascular diseases, diabetes, cancer, obesity, and
other chronic and inflammation-related diseases [12]. In the context of CRC, a
meta-analysis of available epidemiologic studies indicated that soy consumption
was associated with approximately 21% reduced risk of CRC in women [13].
Among the different compounds with biological properties present in soybeans,
the bioactive peptide lunasin has received particular attention over the last two
decades as demonstrated by the large body of literature addressing its
chemopreventive, anti-inflammatory, and antioxidant properties [14]. Lunasin has
been demonstrated to inhibit the NF-κB pathway and downregulate the pro158

inflammatory cytokines TNF-α, IL-6, IL-1β, as well as other molecules involved in
inflammation [15,16]. Mammalian cell lines and in vivo models of melanoma,
skin, and breast cancer provide evidence of the chemopreventive and
therapeutic properties of the peptide [17]. However, the biological activity of
lunasin in the context of IBD and CA-CRC remains unknown. In chapter three,
we demonstrated that oral administration of lunasin can reduce susceptibility to
spontaneous colitis in IL-10 -/- mice serving as a first approach to address the
promising use of the peptide in the context of IBD. In this study, we aimed to
explore the effect of oral administration of lunasin over the development of colon
cancer mediated by inflammation, using an in vivo model of chemically induced
CA-CRC.

4.3 Methods
4.3.1 Isolation of lunasin and preparation of jelly for voluntary oral
administration
Lunasin was isolated from tofu whey as previously described [18]. The
final dry powder corresponded to isolated lunasin with at least 80% purity.
Due to the minimum impact over food intake, easy preparation and
supplementation with water soluble compounds, and soft consistency that make
it easily ingested during periods of stress and sickness, jelly was used as a
vehicle for the dietary supplementation of lunasin. Voluntary self-administration of
the jelly was selected as the mechanism for oral administration, as it allows the
controlled delivery of accurate doses of lunasin, eliminates the risk of injury
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associated with daily oral gavage, and reduces stress associated with restraining
the animals. The jelly was prepared every 5 days using 8% gelatin and 10%
sucralose (purchased from a local store) and kept at 4°C. The placebo jelly did
not contain any additional ingredient, while jelly containing lunasin was
incorporated with the appropriate amount of the peptide to provide a dose of 20
mg lunasin /kg of body weight (BW). Lunasin supplementation corresponds to a
human equivalent dose of 1.6 mg/kg BW according to the method described by
Nair and Jacob [19].
4.3.2 Animals and experimental design
Azoxymethane (AOM) and cyclic administration of dextran sulfate sodium
(DSS) were used to induce CA-CRC in the mice, following previous studies in
inflammation-driven tumor progression in murine models [27]. Sixteen male 8weeks old C57/BL6J mice (Jackson Laboratories, Bar Harbor, ME) were housed
in pairs with free access to water and chow diet provided ad libitum. Housing
facilities were controlled to maintain 23 ± 3 °C, 30-50% relative humidity, and 12
h light/dark cycles. The training was performed to overcome neophobia to the
jelly and promote voluntary oral ingestion. Briefly, after three days of
acclimatization, solid food was removed for eight hours during the dark cycle. At
the end of the fasting period, mice were temporarily moved to individual cages
and a placebo jelly was presented. After consumption of the entire piece of jelly,
the mice were returned to their original cages and allowed free access to solid
food. Placebo jelly was presented for the following three days, without a fasting
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period, to induce the habit of jelly consumption in addition to the regular diet. At
the end of the training period, mice were randomly divided into two groups
AOM/DSS (n=8) and AOM/DSS+Lunasin (n=8). For the remainder of the study
(11 weeks), administration of placebo jelly to the AOM/DSS group, or jelly
containing lunasin to the AOM/DSS+Lunasin group was performed daily.
After one week of daily jelly supplementation, intraperitoneal injection of
AOM (MP Biomedical, Santa Ana, CA) at 10mg/ kg BW was given to every
mouse. One week after AOM injection, 2% DSS (MP Biomedicals, Santa Ana,
CA) was administered in drinking water for seven consecutive days, followed by
14 days of regular water. The DSS administration cycle was performed two more
times using 1% and 1.5% DSS for the second and third cycles, respectively.
Dosage of AOM and DSS were based on previously reported study [25]. The
concentration of DSS was modified for the second and third cycles due to the
severe impact observed after the 2% administration cycle. Consumption of
drinking water was monitored at least twice a week to ensure equal exposure to
DSS. Experimentation was conducted following the U.S. Public Health Service
Policy on Humane Care and Use of Laboratory Animals and ARRIVE guidelines.
Protocol for animal experiments was approved by the Institutional Animal Care
and Use Committee of the University of Tennessee Knoxville (#2786-0920).
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4.3.3 Blood and tissue collection
At the end of the third DSS cycle, blood was collected via cardiac stick
under isoflurane anesthesia as a terminal procedure, immediately followed by
cervical dislocation to confirm death. Blood was left to clot for 30 min at room
temperature and then centrifuged at 1500 x g for 10 min. Serum was collected,
aliquoted, and stored at -80 °C for further analysis. The spleen and the colon
were harvested, and weight and length were measured. The colon was opened,
and the fecal content carefully removed using tweezers. The number of
macroscopic tumors was recorded, and their size (length, width, and height) was
measured using a digital caliper. Tumor volume was calculated according to the
formula V=0.5 (length x width x height). The colon was longitudinally dissected in
two sections. One section was rolled and fixed in formalin for histological
examination. The other section was snap-frozen in liquid nitrogen and stored at 80 °C for further analysis.
4.3.4 Disease activity index (DAI)
Body weight was recorded every three or four days during the first three
weeks, and every day after the first cycle of DSS was initiated. Individual fresh
stool samples were evaluated weekly during the first three weeks and every two
or three days upon initiation of the first DSS cycle. Scores were assigned to
changes in the BW and the stool, based on criteria previously described [25],
with slight modifications as follows: i) loss of relative body weight: 0= no loss or
gain, 1= <5%, 2= between 5 and 10%, 3= between 10 and 15%, and 4= >15%
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compared to the BW at the beginning of the appropriate DSS cycle; ii) stool
consistency: 0= normal stool, 1= moist and sticky, 2= loose pasty stool, 4=
watery diarrhea; iii) hematochezia: 0= no visible blood in the stool, 1= brown
reddish color in the stool, 2= blood present in the stool, 4= gross rectal bleeding.
The DAI was calculated as the sum of the three scores for each mouse, with 0
being the minimum (no disease) and 12 the maximum score (severe disease). In
addition, stool samples were collected from the cages at the indicated time points
and used to evaluate the presence of hemoglobin, as a marker of fecal occult
blood, using previously reported methods [20].
4.3.5 Myeloperoxidase (MPO) activity and cytokines
Extracts from colonic tissue and measurement of MPO activity, as an
indicator of neutrophils infiltration, were performed according to previously
described methods [20]. For assessment of cytokines, tissue extracts were
prepared by homogenizing 50 mg of colonic tissue in 1 mL of T-PERTM lysis
buffer (Thermo Scientific, Waltham, MA) supplemented with 5 µL of protease
inhibitor cocktail (VWR International, Radnor, PA), using 1.0 mm zirconium
beads (OPS Diagnostics, Lebanon, NJ) for 5 min at 30 Hz. Homogenate was
centrifuged and the supernatant was aliquoted and stored at -80 °C until
analysis. The protein content of tissue extracts was quantified using Bradford
assay. Pro-inflammatory cytokines TNF-α and IL-1β were analyzed in colonic
extracts and blood serum using commercially available ELISA kits (Biolegend,
San Diego, CA) according to the protocol provided by the manufacturer.
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4.3.6 Western Blot
Colonic tissue extracts for cytokine analysis were used to perform western
blot immunoassay. Briefly, 20 µg of protein were separated via gel
electrophoresis following standard protocol. Then Trans-Blot Turbo transfer
system (Bio-Rad, Hercules, CA) was used to transfer the proteins into
polyvinylidene difluoride membranes. After 1 h blocking with 5% non-fat dry milk
in 0.01% Tween 20 Tris-buffered saline (TBST), membranes were incubated
overnight at 4 °C with Bcl-2-associated X protein (BAX), X-linked inhibitor of
apoptosis protein (XIAP), Caspase-3, E-Cadherin, Claudin 3 and β-actin primary
antibodies (Proteintech, Chicago, IL) at 1:1000 dilution. The next day membranes
were washed three times with TBST, and then incubated with secondary
antibody at 1:2000 dilution for 1 h at room temperature. Membranes were imaged
using a C-Digit Blot scanner (LI-COR Biosciences, Lincoln, NE) and the optical
density of the immunoreactive bands was analyzed using Image StudioTM
software.
4.3.7 Histopathological assessment
Formalin-fixed colonic tissue was paraffin-embedded, cut into 4 µm
sections and routinely stained with hematoxylin and eosin- (H&E). Sections of
colon were assessed for inflammation, dysplasia, and neoplasia in a blinded
fashion by a board-certified anatomic pathologist (MMS). Inflammation was
evaluated in areas not affected by dysplasia, and the scoring was performed
according to the guidelines published by Erben et al. [21], based on the following
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criteria: i) changes in mucosal architecture: 0= none, 1= focal erosion, 2=
multifocal erosion and/or evidence of focal ulceration, and 3= evidence of
extended ulceration with granulation tissue; ii) goblet cell depletion: 0= minimum
or no evident changes, or 1= evident decrease in the population of goblet cells;
iii) density of inflammatory cellular infiltration: 0= no observed, 1= < 10% of the
tissue, 2= 10 to 25%, 3= 26 to 50%, and 4= > 51%; iv) extent of infiltration: 1=
limited to the mucosa, 2= mucosa and submucosa, and 3= transmural infiltration.
The inflammation score was calculated as the sum of the four individual scores,
with 11 being the maximum possible score. Dysplastic lesions were classified as
indefinite dysplasia or hyperplasia, low-grade dysplasia with nuclei remaining in
basilar location, high-grade dysplasia with nuclei which span height of cell, and
invasive carcinoma [22].
4.3.8 Statistical analysis
Results are reported as mean ± SEM. The non-parametric Mann-Whitney
test or the parametric Student t-test were applied accordingly to identify
significant differences (p< 0.05). Statistical analyses were performed using the
software Minitab ® 17.1.0 (Minitab Inc., USA) or Excel Microsoft 365 (Microsoft
Corporation, USA).

4.4 Results
4.4.1 Lunasin facilitated the recovery of body weight and stool consistency.
Variations in the BW relative to the individual BW at the beginning of each
DSS cycle are presented in Figure 4.1A. Loss of BW is common in patients with
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CD due to the impairment in the digestive and absorptive functions of the
intestine, but it only occurs in the most severe cases of UC [23]. This fact agrees
with the lack of effect observed over the relative BW when DSS was
administered at the lowest dose, in contrast to the marked and very drastic drop
in BW when higher concentrations were used. Although significant differences
between the two groups were found only during the last 10 days of the study,
records from daily monitoring indicated that 75% and 38% of the mice in the
AOM/DSS group and the lunasin treatment group, respectively, lost more than
14% of BW during the first DSS cycle. Administration of 1.5% DSS (third cycle)
resulted in more than 8% loss of BW in 3 mice from the AOM/DSS group and
only 1 mouse in the AOM/DSS + lunasin group.
The average DAI (Figure 4.1B) clearly shows three peaks that are
proportional to each cycle of DSS. Upon inflammatory flares, decrease of the DAI
to a minimum level took 15 days after the first cycle and 2 days after the second
cycle for both groups, but 15 days for AOM/DSS and 5 days for AOM/DSS +
Lunasin group after the third cycle. These results suggest that an extended
period is required for the recovery of mild (1.5% DSS) and severe (2.0% DSS)
episodes of inflammation and that lunasin significantly accelerated the recovery
from inflammation when CA-CRC was already established. This faster recovery
seems to be concomitant to the observed improvement in BW. Significant
differences particularly on days 48, 54, and 67 were associated with favorable
changes in stool consistency. Overall, when lunasin was given, a score of 0 (no
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signs of disease) was 10% more frequent, while scores associated with any level
of disease were less common (Figure 4.1C).
No significant differences were observed in the hemoglobin content
(Figure 4.1D) between the two groups. However, as shown by hematochezia
scores (Figure 4.1E), one mouse in the AOM/DSS group exhibited gross rectal
bleeding, while none did in the AOM/DSS + Lunasin group. Lunasin also
contributed to a faster recovery of the stool regular consistency (Figure 4.1F) as
observed in the trends of the scores following the second and third inflammatory
peaks. Four episodes of diarrhea were observed in each group, but only during
the first cycle (Figure 4.1G). It is to be noted that watery diarrhea in the
AOM/DSS + Lunasin group was observed in two mice that overall showed a low
response to the peptide. Analysis of the frequency of the scores indicated that
mice receiving lunasin were 5% and 8% less prone to exhibit any indicator of
potential blood in the stool and change of stool consistency, respectively.
4.4.2 Lunasin treated mice had lower relative spleen and colon weight.
Spleen enlargement is a common feature in DSS-induced colitis [24] and
CA-CRC [25]. In mice administered with lunasin, the relative spleen weight
(Figure 4.2A) and the relative colon weight (Figure 4.2B) were significantly lower,
by 0.6 mg/g and 4 mg/g, respectively. As no statistical differences were found in
the length of the colon between the groups (Figure 4.2C), the increased colon
weight in the non-treated mice was associated with the presence of inflammation
and tumors.
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4.4.3 Lunasin reduced histological markers of inflammation.
On average, AOM/DSS mice exhibited moderate cellular infiltration
(Figure 4.3A) that was extended transmurally through the mucosa, submucosa,
and muscularis externa (Figure 4.3B), accompanied by multifocal areas of
erosion, evidence of previously extended ulcers, and granulation tissue (Figure
4.3C). Lunasin supplementation significantly reduced the density of cellular
infiltration. Although transmural infiltration was found in 50% of the mice in this
group, 38% had infiltration limited to the mucosa only. No evidence of extended
ulcers or granulation tissue was found in this group, and 38% of the mice did not
exhibit any sign of mucosal inflammatory damage. With exception of one mouse
in the AOM/DSS group, no overt ulcers were found in general, indicating that the
14 days of recovery after the last cycle of DSS administration allowed for a
considerable extent of mucosal healing. Also, 50% of the mice in the AOM/DSS
group exhibited evident depletion of goblet cells, while only 25% in the AOM/DSS
+ lunasin group did (p= 0.347). Overall, the inflammatory score was 8 for the
AOM/DSS group, and 5 for the AOM/DSS + Lunasin group (Figure 4.3D).
Although the difference was not statistically significant, there was an evident
favorable response in three of the mice across all the evaluated parameters,
suggesting that this subset of mice was highly responsive to the therapeutic
effect of the peptide. The trend observed in MPO activity (Figure 4.3E) indicated
that neutrophil activity was about 50% lower in the AOM/DSS + lunasin group,
which is consistent with histological evaluation of cellular infiltration. Figure 4.3F
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presents representative micrographs of H&E staining of colonic tissue for each
group, indicating the evaluated parameters previously described.
4.4.4 Lunasin reduced tumor burden and malignant histological features.
Pictures of colons showing the presence of tumors are presented in Figure
4.4A. The AOM/DSS group had 100% of tumor incidence with an average of four
macroscopic tumors per mouse (Figure 4.4B). In contrast, the AOM/DSS +
Lunasin treatment group had a 75% tumor incidence with an average of two
macroscopic tumors per mouse, indicating a 50% reduction in tumor multiplicity.
The maximum number of tumors detected in a single mouse in the AOM/DSS
group was 10, while, for the AOM/DSS + Lunasin group, it was four. Mice bearing
the highest number of tumors also corresponded to the highest relative colon and
spleen weight in their respective groups. No differences were found in the
average accumulative tumor volume (p=0.273, Figure 4.4C).
The histopathological evaluation indicated that every mouse in the
AOM/DSS group developed several polypoid masses with multifocal dysplastic
lesions ranging from hyperplasia to high-grade dysplasia (Table 4.1), with 25% of
the mice having invasive carcinoma. Lunasin administration abrogated any kind
of dysplastic lesion in 50% of the mice and inhibited the development of
carcinomas, suggesting that the peptide significantly prevented abnormal cell
growth. Figure 4.4D shows representative micrographs of the dysplastic regions
found in both groups.
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4.4.5 Lunasin decreased serum levels of TNF-α.
Assessment of pro-inflammatory cytokines (Figure 4.5) revealed that
lunasin did not significantly affect the average levels of IL-1β in the colon or the
serum, but there was a significant reduction of TNF-α by 70% in the blood.
Although colonic levels of TNF-α between the two groups were not significantly
different, the mice with the highest concentration of colonic TNF-α in each group
corresponded with the highest observed level of MPO activity, the presence of
overt ulcers, and high histological inflammation scores, suggesting that these
mice had unresolved inflammation at the end of the study.
4.4.6 Lunasin administration resulted in higher levels of E-cadherin but not
of apoptotic markers.
Protein levels of the adherent junction E-cadherin (Figure 4.6A) was
significantly increased by 40% in mice treated with lunasin (p=0.049), while the
tight junction Claudin-3 (Figure 4.6B) was increased by 20% (p=0.133). These
results suggest a partial effect of the peptide over molecules involved in the
maintenance of the epithelial barrier. Evaluation of the pro-apoptotic markers
BAX (Figure 4.6C) and cleaved caspase-3 (Figure 4.6D) indicated a nonsignificant increase of 30% in the colon of mice supplemented with lunasin
(p=0.064 and p=0.213, respectively). No significant differences were found
between AOM/DSS and AOM/DSS + Lunasin groups (p=0.382) when comparing
the protein levels of the anti-apoptotic marker XIAP in mice affected by
inflammation. However, it is worth mentioning that in the subset of mice highly
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responsive to lunasin, with no signs of dysplasia, mucosal damage, and low
inflammation scores, a 7-fold increase in XIAP was observed in contrast to the
average levels in less responsive mice from the same treatment group (p=0.022).

4.5 Discussion
In murine models, cyclic administration of DSS results in chronic colitis
[26]. When combined with the genotoxic carcinogen AOM, the model
recapitulates colorectal carcinogenesis driven by inflammation and resembles the
key features observed in human disease [27]. The administration of AOM and
DSS resulted in relapsing episodes of moderate to severe inflammation,
characterized by a significant decrease of BW, diarrhea, and rectal bleeding
(Figure 4.1). Daily supplementation of lunasin led to a significant improvement in
the BW when CA-CRC was established, and faster recovery from diarrhea-like
symptoms as indicated by an early return to regular stool consistency after
episodes of mild and moderate inflammation. IBD patients face typically four
episodes of diarrhea per day [23], making it one of the most predominant and
debilitating symptoms of the disease [28]. Although lunasin did not fully prevent
episodes of severe watery diarrhea from happening after the inflammatory peak,
harder stool consistency was achieved from 2 to 10 days earlier in mice under
lunasin supplementation (Figure 4.1F). These observations suggest that the
peptide might facilitate or promote repair mechanisms that reduce the abnormal
presence of water in the stool that causes stool softening.
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In IBD, altered function, localization, or expression of the tight and
adherent junctions that regulate paracellular flux result in the breakdown of the
intestinal barrier function, leading to diarrhea via the backflow of absorbed
solutes and water [28]. Downregulation of the tight junction molecule claudin-3
[29] and the adherent junction E-cadherin [30] has been reported in IBD patients,
and in animal models of intestinal inflammation induced by DSS [31]. The higher
levels of E-cadherin in the colon of mice receiving lunasin (Figure 4.6A) suggests
that the peptide might contribute to the recovery of the colonic epithelial integrity.
Lunasin has been shown to induce gene and protein expression of E-cadherin in
murine HC11 mammary cells [32,33], and to have a slight promotor effect in
human KM12L4 colon cancer cells [34]. This is the first report indicating the
potential effect of lunasin on E-cadherin levels in vivo. Downregulation of Ecadherin in inflamed tissues has been particularly found to occur in areas of
ulceration [35]. Massive infiltration of neutrophils is a hallmark of UC and is
accompanied by the release of reactive oxygen species, serine proteases, MPO,
and matrix metalloproteinases [36]. It has been demonstrated that E-cadherin is
cleaved by the proteolytic activity of neutrophil elastase [37]. Under this scenario,
the initial damage to the colon caused by DSS results in severe neutrophil
infiltration in ulcerated areas, accompanied by the cleavage of E-cadherin,
causing further disruption of the epithelial barrier. In consequence, the disrupted
paracellular efflux allowed back flux of water to the lumen, resulting in softening
of the stool and diarrhea-like symptoms. The multifocal ulceration and extensive
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dense cellular infiltration observed in the intestinal wall of AOM/DSS mice was
significantly alleviated by lunasin treatment (Figure 4.3A). This was accompanied
by a marked decrease in MPO activity (Figure 4.3E), corroborating a reduced
presence of neutrophils. It is possible that after removal of DSS, lunasin
decreased the presence and activity of neutrophils in the tissue, facilitating the
maintenance of E-cadherin. This contributed to the progressive recovery of the
epithelial barrier and appropriate regulation of paracellular efflux, as manifested
by the positive change in stool consistency (Figure 4.1F).
Inflammation plays an important role in CA-CRC by creating a favorable
environment that stimulates oncogenic pathways, favors the survival of tumorinitiating cells, promotes tumor growth, and influences metastasis [38]. It is
believed that inflammatory cells, via reactive oxygen species and nitrogen
reactive intermediates, create a highly reactive and mutagenic environment [38].
Simultaneously, the resistance to cell death mediated by pro-inflammatory
pathways increases the chance of survival of mutation-bearing cells. Thus, the
wound-healing-regeneration response promotes the proliferation of mutant cells,
giving place to tumor formation. Local repetitive injury and chronic inflammation,
not only facilitate tumorigenesis but also contributes to tumor progression [38]. In
this study, histological observations of normal epithelium overlying areas with
mixed inflammation and crypt loss suggested mucosal healing of previous
ulcerative injuries created during the flare (Figure 4.3C). The prolonged period of
recovery after the last DSS cycle allowed for local mucosal repair and resolution
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of acute inflammation by the end of the experiment, explaining the lack of
significant differences between the two groups in the average colonic levels of
the pro-inflammatory mediators TNF-α and IL-1β (Figure 4.5). However, it is
known that during active inflammatory flares these pro-inflammatory signals are
highly expressed by resident and infiltrating immune cells [11]. The effect of
lunasin over pro-inflammatory signals has been studied and demonstrated in
vitro [14]. In chapter 3 it was demonstrated that oral administration of lunasin
significantly decreased TNF-α and IL-1β in the colon of an in vivo model of
spontaneous colitis (Figure 3.2), suggesting that lunasin can exert antiinflammatory activity in the bowel. Hence, it is reasonable to speculate that
during the active flares lunasin could have attenuated to some extent the storm
of pro-inflammatory cytokines in the colon, at least by reducing the presence of
infiltrating immune cells, as observed in the tissues and corroborated by MPO
activity trend (Figure 4.3). The high tumor multiplicity generated by the AOM/DSS
treatment was significantly abrogated by lunasin (Figure 4.4B) and accompanied
by a 70% decrease in the serum levels of TNF-α (Figure 4.5B). It is possible that
the effect observed over tumor incidence and burden was mediated, at least
partially, by the anti-inflammatory properties of lunasin. It is worth pointing out
that, although no differences were found in average colonic levels of TNF-α, mice
with detected carcinoma exhibited 2-fold increased concentration in comparison
to their group peers, suggesting the potential involvement of this cytokine and
inflammation in the carcinogenic process. Cell cycle arrest at the G2/M phase
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and induction of caspase-3 -mediated apoptosis, via the upregulation of BAX and
downregulation of BCL-2 in vitro, have been shown to reduce the proliferative
potential of colorectal and mammary cancer cells treated with lunasin [15].
However, intraperitoneal injection of lunasin in a model of metastatic colorectal
cancer significantly reduced metastasis to the liver with no significant effect over
the pro-apoptotic markers [39], which is consistent with our observations in the
protein levels of BAX and caspase-3 in the colon (Figure 4.6). In addition to its
involvement in apoptosis, XIAP plays an important role in the regulation of
intestinal immunity and inflammation in IBD [40]. XIAP deficiency has been
reported to cause a very early onset of intractable colitis [41]. Then, it is possible
that the increased levels of this protein might have contributed to the observed
favorable outcomes in mice with increased response to lunasin treatment.
Further mechanistic investigation is necessary to establish the potential
involvement of lunasin in the upregulation of XIAP.
Enlargement of the spleen has been previously reported in DSS-induced
UC [24] and CA-CRC [25] and is considered a marker of disease severity and
systemic inflammation [42]. We observed a significant reduction of the relative
spleen weight in mice supplemented with lunasin (Figure 4.2A). Intraperitoneal
injection of lunasin has been shown to significantly decrease the enlarged spleen
weight of male mice fed with a high-fat diet in a model of obesity-induced
inflammation [43]. As such, the effect of lunasin over serum levels of TNF-α and
the spleen weight suggests that the biological activity of the peptide, even upon
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gastrointestinal digestion, is not limited to the large intestine but could directly or
indirectly have an impact at the systemic level. Extraintestinal manifestations are
observed in 25 to 40% of IBD patients and affect the eyes, skin, liver, joints,
skeletal muscle, kidneys, lungs, as well as metabolic processes [44]. Some of
these manifestations such as arthritis, erythema nodosum, pyoderma
gangrenosum, iritis, and uveitis, have been demonstrated to have a pathogenic
mechanism mediated by TNF-α [45]. Then, the anti-inflammatory effect of
lunasin, and particularly its impact on the systemic levels of TNF-α, could be
beneficial not only in the bowel but also in some of the extraintestinal
manifestations of the disease.
In contrast to sporadic CRC that follows the adenoma-carcinoma
sequence, CA-CRC progresses through the inflammation-dysplasia-carcinoma
sequence that involves inflammation, low-grade, high-grade dysplasia, and
eventually invasive carcinoma [46]. Dysplasia in CA-CRC represents a premalignant phase [47]. In our observations, Table 4.1, all mice in the untreated
group developed some grade of dysplasia, with half of them exhibiting high-grade
dysplasia and 25% invasive carcinoma. Administration of lunasin fully abrogated
dysplasia in 50% of the mice and delayed the progression of the sequence in
another 25%. Genomic alterations that affect genes engaged in cell proliferation,
death, and differentiation are highly encountered in CRC and CA-CRC. Mutation
in p53, a protein that prevents the clonal expansion of mutant cells, is an early
event in CA-CRC that has been found in inflamed mucosa, near 33% of low176

grade, 63% of high-grade dysplasia, and 85% of cancerous lesions [48]. Loss of
tumor suppressor genes such as APC, and activation of the proto-oncogenes kras and c-src, are also important in CA-CRC but usually occur as late events
[48]. Regular surveillance colonoscopy, starting 8 to 10 years after diagnosis of
UC, accompanied by random biopsy, is recommended for the early detection of
dysplastic alterations, and polypectomy or proctocolectomy is usually performed
when high-grade dysplasia is detected in flat mucosa [4]. Our results indicate that
lunasin can potentially delay or minimize the genomic processes involved in the
abnormal growth of cells that results in dysplastic lesions, and their malignant
progression towards cancer. Hence, it would lessen the need for preventive
removal of sections of the large intestine.
In conclusion, it was demonstrated for the first time the anti-inflammatory
and chemopreventive properties of lunasin in a model of relapsing UC and CACRC. The oral administration of lunasin decreased the impact of inflammation
over the colon, reduced tumor incidence, and multiplicity, and delayed the
progression of malignant features, by favoring the recovery of the epithelial
barrier integrity and reducing the susceptibility to neoplastic initiating events
during the inflammatory flares. Our findings provide an alternative mechanism to
facilitate the control of underlying inflammation during UC and to prevent the
development of CA-CRC, which in consequence would contribute to the
improvement in the life expectancy and quality of IBD patients, and particularly in
those affected by refractory forms of the disease.
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Figure 4.1 Macroscopic markers of the disease.
(A) Variation of the average relative body weight, (B) Average and (C) Frequency
for disease activity index (DAI) scores, (D) Hemoglobin content in stool as an
indicator of occult fecal blood, (E) Frequency for hematochezia score, (F)
Average and (G) Frequency for stool consistency score. Results are presented
as average ± SEM. * Indicate significant differences (p<0.05) between AOM/DSS
and AOM/DSS + Lunasin groups. Over the last 10 days of the experiment, the
relative body weight of the AOM/DSS + Lunasin group was significantly higher
than the relative body weight for the AOM/DSS group (indicated by a horizontal
bar).
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Figure 4.2 Effect of lunasin over spleen and colon.
(A) Relative spleen weight, representative pictures of the spleens as insets, (B)
Relative colon weight, and (C) Representative pictures of colon length, with white
arrows indicating tumors. Results are presented as average ± SEM.
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Figure 4.3 Evaluation of histopathological markers of inflammation
Scores for (A) Density of cellular infiltration, (B) Extent of infiltrate, (C) Mucosal
architecture, and (D) Total inflammation. (E) Quantification of MPO activity in the
colon, (F) H&E micrographs of areas affected by inflammation. Scale bars
(bottom right) is 275 µm. Arrows in (F) indicate cellular infiltration (black), goblet
cell depletion (white), and erosion (blue). Results are presented as average ±
SEM.
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Figure 4.4 Tumor burden and dysplasia.
(A) Representative pictures of longitudinally opened colons indicating tumors
(white arrows), (B) Total number of tumors per mouse, (C) Cumulative tumor
volume, and (D) H&E micrographs of colon sections from each treatment group
indicating polypoid dysplastic masses (black squares) and representative
pictures of L: low, H: high, and I: indefinite dysplasia, and C: carcinoma. Results
are presented as average ± SEM.
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Table 4.1 Number of mice exhibiting the indicated grade of dysplasia.
Dysplasia AOM/DSS
None
Indefinite
Low
High
Carcinoma

0
4
4
4
2

AOM/DSS
+ Lunasin
4
1
3
2
0
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Figure 4.5 . Colonic and systemic levels of pro-inflammatory cytokines.
Levels of pro-inflammatory cytokines TNF-α (A and B) and IL-1β (C and D) in the
colon (A and C), and in the blood serum (B and D). Results are presented as
average ± SEM.
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Figure 4.6 Markers of epithelial integrity and apoptosis.
Relative protein levels of (A) E-Cadherin and (B) Claudin-3 as indicators of
epithelial integrity, and (C) BAX and (D) Caspase-3 as indicators of apoptosis.
Results are presented as average ± SEM. A.U.: Arbitrary units.
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CHAPTER 5. CONCLUSION AND FUTURE DIRECTIONS
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5.1 Conclusion
In this study, a three-step process for the isolation of bioactive lunasin
(>80% purity) from tofu whey was designed. The process involves ethanolic
removal of high molecular weight proteins, acidification of the clarified whey to
induce the separation of lunasin enriched material, and purification via
preparative gel filtration chromatography. The designed process is competitive
with current isolation mechanisms but faster and easier and allows the
valorization of a waste product generated in large quantities by the soybean
industry. Lunasin reduced the susceptibility of IL-10-/- mice to minor inflammatory
events, which was reflected in a lower frequency of macroscopic manifestations
of the disease. The decreased levels of pro-inflammatory cytokines in the small
and large intestines indicated that upon oral administration, lunasin or its
digestion products reached and exert anti-inflammatory activity in all the sections
of the bowel. The anti-inflammatory activity of lunasin was partially mediated by
the inhibition of the NLRP3 inflammasome via the downregulation of the NLRP3
protein, and independent from mitochondrial ROS and potassium efflux.
Moreover, lunasin exerted chemopreventive properties in the colon by reducing
tumor incidence and multiplicity, mitigating the malignant transformation of
dysplastic lesions, and attenuating the damage resulting from the chemically
induced inflammatory flares.
Overall, this study for the first time proposed and addressed the isolation
of bioactive lunasin from a liquid byproduct of the soybean industry,
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demonstrated the anti-inflammatory and chemopreventive properties of lunasin in
the bowel, and showed the modulatory effect of lunasin over the NLRP3
inflammasome. Furthermore, it served to prove in vivo the biological activity of
the products resulting from the gastrointestinal digestion of lunasin when orally
consumed.
The incorporation of lunasin in the diet could be partially achieved by the
consumption of soybean products. However, the low bioavailability of the
peptide, and the limited amount of lunasin could post a challenge for the peptide
to reach the bowel as a target site in appropriate concentrations, as it would be
absorbed and passed to the systemic circulation. Generation of lunasin
supplements or the incorporation of purified forms of the peptide in vehicle foods,
as imitated in the last chapter, could be helpful to achieve an increased intake,
and activity in the bowel. Possible interactions between the food matrix and
lunasin, as well as changes in the biological activity resulting from food
processing steps and storage, require further investigation.

5.2 Future directions
Further research to gain a better understanding of the potential utilization of
lunasin in gastrointestinal disorders might include:
•

Identification of the products resulting from the in vivo digestion of lunasin
and their biodistribution in the different sections of the bowel, as well as
the potential correlation between structure and activity.
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•

Variation in the composition and functionality of the intestinal microbiota
because of lunasin consumption in healthy and diseased conditions, as
well as the effect of lunasin and digestion-derived peptides over the
crosstalk between epithelial, immune, and microbial cells.

•

Potential chemopreventive activity of lunasin against sporadic and familiar
forms of CRC, as well as the potential contribution of orally consumed
lunasin in extraintestinal manifestations of IBD.

Research ideas inspired in the outcomes and results observed in this
research, but not related to gastrointestinal health include:
•

Effect of lunasin over other inflammasome structures, and the potential
utilization of the peptide in diseases with a critical contribution of the
inflammasomes.

•

Causes underlying differential outcomes between individuals that show
either high or low response to the peptide.
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